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Abstract
The prevalence of autism has increased in an exponential way in the past few years. 
Many monogenetic mutations as well as copy number variants and single nucleotide 
polymorphisms have been associated with autism spectrum disorders (ASD), a large pro‐
portion of which occur in genes associated with synaptogenesis and synaptic function. 
However, the increase in appearance of genetic alterations does not explain the etiol‐
ogy of an elevated number of ASD cases. Recent research is now focusing on the role 
of environmental/epigenetic factors, which by themselves and/or in combination with 
classical genetic factors, may be the root cause of a large number of ASDs. In this chap‐
ter we review the current literature regarding the epigenetic changes involved in ASD, 
including their possible mechanisms of action such as oxidative stress, altered fatty acid 
metabolism, mitochondrial dysfunction, DNA methylation and histone methylation 
(via the one‐carbon metabolism cycle), histone variants, and ATP‐dependent chromatin 
remodeling. We discuss possible new biochemical markers related to autism as well as 
new lines of research for therapeutic targets.
Keywords: ASD, autism, children, betaine, choline, genetics, epigenetics, fatty acid, 
lipid, one‐carbon metabolism cycle, PUFAs, peroxidation, methylation, mitochondrial 
dysfunction, oxidative stress, phospholipases, research
1. Introduction
Autism spectrum disorder (ASD) etiopathogenesis occurs result of a complex, engaging mul‐
tiple environmental factors and epigenetic modifications, interacting with the genetic basis 
of the developmental processes. Although the ADS‐risk genes are numerous, and many of 
them have a dual function involved in different neural networks, they seem to converge in a 
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limited number of molecular pathways. It has been proposed that genes implicated in “mono‐
genic” variants of syndromic and nonsyndromic ASD converge on molecular pathways and 
mechanisms related to synaptic dysfunction also known as “developmental synaptopathy.” 
The interplay between mutations in different genes can produce “idiopathic” autism, but the 
exposure to environmental modifiers as well as epigenetic factors may add up to a varying 
expression of autistic features, allowing to define autism as “synaptic and chromatin‐remod‐
eling disorders.”
Congenital epigenetic diseases are a newly delineated group of multiple congenital anomalies, 
intellectual disabilities, and ASD syndromes resulting from “Classical imprinting disorders” 
and “Mendelian disorders of the epigenetic machinery.” The advances in the identification of 
the DNA‐methylation level of specific genes, histones modifications (highlighted dysregula‐
tion of histone methylation as a major contributing factor), histone variants, and ATP‐depen‐
dent chromatin remodeling complexes throw light about the epigenetic effects of nongenetic 
biological risk factors and environmental factors in ASD.
Currently, new biochemical markers have been implicated in the etiology of autism, such as 
increased oxidative stress and lipid peroxidation, phospholipase release of fatty acid, and 
the formation of toxic metabolites, mitochondrial dysfunction, or alteration of DNA‐methyla‐
tion. In addition, other relevant epigenetic mechanisms such as impaired methylation via the 
“one‐carbon metabolism cycle” including the folate metabolism, the methionine‐homocys‐
teine remethylation cycle (involving choline and betaine), and the transsulfuration pathway 
also help to complete the difficult puzzle of autism.
Therefore, epigenetic mechanisms constitute new lines of research and may open the door 
for new targets in the treatment of autism. The epigenetic changes are potentially reversible, 
and, therefore, a thorough understanding of these modifications may identify new therapeu‐
tic targets for the disease. So finally several questions arise: Is autism also an acquired and 
therefore preventable, treatable, and potentially curable epigenetic disease? Could alteration 
in diet and fat supplementation result in neuronal repair and reverse the deficit in autism? 
How could this knowledge be applied to clinical practice?
In this chapter, we conducted an updated review of the role of genetic and epigenetic changes 
involved in the pathophysiology of ASD including their possible mechanisms of action. We 
also included the latest lines, perspectives, and future directions of therapeutic approaches.
2. The etiopathogenesis of ASD
The autism, a debilitating neurological handicap in children, is a highly heterogeneous set 
of disorders with wide variations in symptom severity, intellectual level, and functional dis‐
ability. Classically in DSM IV‐TR [1] “Pervasive developmental disorders” (PDD) encompass a 
heterogeneous group of children characterized by severe and pervasive impairment in several 
areas of development: (1) reciprocal social interaction skills, (2) communication skills, and (3) 
the presence of stereotyped behavior, interests, and activities. The qualitative impairments 
that define these conditions are distinctly deviant relative to the individual's developmental 
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level or mental age. The specific disorders included five subtypes in this section: autistic disor‐
der (AD), Rett's disorder (RD), childhood disintegrative disorder (CDD), Asperger's disorder, 
and pervasive developmental disorder not otherwise specified (PDD‐NOS). These disorders 
are usually evident in the first years of life and are often associated with some degree of 
 “intellectual disability.”
At present, a new edition of the DSM (“Diagnostic and Statistical Manual of Mental 
Disorders,” from the American Psychiatric Association) has been published: DSM‐5® [2]. In 
the new DSM‐5 there is a single category of ASD (autism spectrum disorder) instead of five 
subtypes, and has deleted the term “pervasive developmental disorders.” Scientific evidence 
and clinical practice show that a single spectrum better reflects the symptom presentation, 
time course, and response to treatment. ASDs is a new DSM‐5® name that reflects a scien‐
tific consensus of four previously separate five subtypes disorders, and are actually a single 
condition. The three domains of DSM IV are combined into two core domains: (a) Deficits in 
social communication and social interaction. The rationale is that deficits in communication 
and social behaviors are inseparable. Social communication domain will be created by merger 
of key symptoms from the DSM‐IV social and communication domains. This de‐emphasizes 
language skills not employed in the context of social communication. (b) The second major 
criterion remains restricted repetitive behaviors, interests, and activities (RRBs).
In multiple communities of the United States (CDC surveillance data, 2010) [3], the overall 
prevalence of ASD was 14.7 per 1000 (1 in 68) children aged 8 years. Overall ASD preva‐
lence estimates varied among sites from at least 5.7 to 21.9 per 1000 children aged 8 years. 
Consistent with previous reports, findings were marked by significant variations in ASD 
prevalence by geographic area, sex, race/ethnicity, and level of intellectual ability. The extent 
to which this variation might be attributable to diagnostic practices, underrecognition of ASD 
symptoms in some racial/ethnic groups, socioeconomic disparities in access to services, and 
regional differences in clinical or school‐based practices that might influence the findings in 
this report is unclear.
The importance of accurately identifying individuals with autism has never been greater, 
particularly given the growing prevalence [4], considerable family and societal costs [5], and 
recognized importance of early diagnosis and intervention. The ASD frequency has been 
increasing for decades, with an astonishing 556% reported increase in pediatric prevalence 
between 1991 and 1997 (a prevalence higher than that of spina bifida, cancer, or Down syn‐
drome). Even though researchers cannot agree on whether the trend is a result of increased 
awareness, improved detection and changing diagnostic criteria with expanding defini‐
tion and reduced stringency of diagnostic criteria, rather than to new environmental influ‐
ences and other factors of unknown nature [6, 7]. The classification systems used strongly 
affect prevalence studies, and is important to consider the changes that have occurred at this 
level when analyzing the possible causes of the increase in previously known as pervasive 
developmental disorders [8]. But this increased ASD prevalence cannot be attributed entirely 
to “nonetiological factors” such as changes in reporting practices, diagnostic ascertainment, 
and “diagnostic substitution” (i.e., ID diagnoses decreased at the same time ASD diagnoses 
increased) [9–11].
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Because people with autism can have very different features and symptoms with very high 
degree of phenotypic heterogeneity, autism is a multifactorial condition and is thought of 
as a spectrum disorder [12, 13]. Autism is one of the most complex heritable disorders, and 
a paradigmatic complex genetic disorder, with convincing evidence for genetic factors and 
little or no support for the influence of the environment factors [14]. However, it is essential 
that the ASD not be reflected alone in overly restrictive genetic approaches if we want to 
better understand its pathogenesis. Today, different studies support that the etiopathogen‐
esis of ADS involves an interaction between both susceptible genetic loci and a wide range 
of environmental risk factors on the developmental trajectory. So the pathogenesis of ASD 
is considered an authentic “puzzle,” for a multifactorial threshold model underlying ASD 
with all types of genetic variation (SNV/indel/CNV in coding and noncoding DNA, germline, 
somatic, epigenetic) and environmental factors (the most significant: toxic, immune dysregu‐
lation, and nutritional status) involved in clinical, neuropsychological, and neurobiological 
perspectives [13, 15–18].
Since there are no definitive biological markers of autism, for a majority of cases, diagnosis 
depends on a range of behavioral signs. But advances in system biology are becoming stra‐
tegic for carrying out knowledge on the ASD etiology and for early diagnosis. The most rel‐
evant metabolic pathways and discriminant metabolites in ASD belong among other, amino 
acid metabolism, antioxidant status, mitochondrial metabolism, nicotinic acid metabolism, 
and altered fatty acid metabolic pathways. So, for the study of this “autism epidemic” it is 
of great interest to identify risk factors (genetic and nongenetic) as well as metabolic routes 
that can contribute to ASD; but not separately if not collectively and simultaneously through 
common pathways, allowing to insert the pieces of the ASD puzzle together. That is, from the 
approach to the different disciplines: genomics, epigenomics, metabolomics, and environ‐
mental metabolomics.
3. Genetic in ASD
Children with dysmorphic features, congenital anomalies, intellectual disability, or fam‐
ily members with developmental disorders are those most likely to benefit from extensive 
medical testing and genetic consultation. Increased diagnosis of ASD associated with genetic 
abnormalities has allowed its new specification in the DSM5: “associated with known medical 
or genetic condition.” However, for children with “nonsyndromic or idiopathic” autism the 
studies of genetic risk factors have been less conclusive
3.1. ASD associated with “known medical or genetic condition”
It is known that several monogenic disorders (Mendelian disorders) are associated with 
autism. The most common of these single‐gene defects, including CGG trinucleotide repeats 
within the FMR1 gene as the cause of Fragile X syndrome, mutations in the MECP2 gene in 
Rett syndrome and related disorders, tuberous sclerosis, and PTEN mutation account for but 
a small minority of cases (for up to 5% of ASDs) [19]. Less often and among other genetic 
diseases consistently associated with autism include: rare genetic developmental disorder 
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(inter alia examples the Cohen syndrome caused by a mutation in the vacuolar protein sort‐
ing 13B (VPS13B) gene on locus 8q22‐8q23, or the Smith‐Lemli‐Opitz syndrome caused by 
mutations in the DHCR7 gene on locus 11q13.4 leading to deficiency of the enzyme 3 beta‐
hydroxysterol‐delta 7‐reductase); and metabolic diseases like phenylketonuria, adenylo‐
succinate lyase deficiency, or mucopolysaccharidosis III (Sanfilippo syndrome). (For more 
comprehensive listing see [20].)
There are also many anecdotal reports of autism with visible chromosomopathies [21, 22], and 
Down syndrome have been found with high rates of ASD of up to 42% [23]; and well‐known 
microdeletion syndromes like 22q11 deletion syndrome divided into distinct syndromes (e.g., 
DiGeorge syndrome, velocardiofacial syndrome, and cardiofacial syndrome) in which more 
than 40% meet the criteria for either ASD, ADHD, or both [24]; as well as Angelman syn‐
drome, or Smith‐Magenis syndrome, are well known autism. Although the latter mentioned 
can be produced by different genetic mechanisms, Angelman syndrome is caused by dele‐
tion of the 15q11.2‐q13 critical region (60–75%), paternal uniparental disomy (2–5%), imprint‐
ing defect (2–5%), and mutation in the UBE3A gene (10%); and Smith‐Magenis syndrome is 
caused either by a 17p11.2 deletion encompassing the retinoic acid‐induced 1 (RAI1) gene 
(90%) or a mutation of the gene (10%) [25].
Currently, these diagnosable medical conditions, cytogenetic abnormalities, and single‐gene 
defects together account for <10% of cases of ASD. The latest advances made in genetics and 
technology, mainly the widespread use of molecular techniques by chromosomal microar‐
ray studies have increased the diagnostic cost‐effectiveness of conventional techniques 
(karyotype, subtelomeric analyses, etc.) from 3–5% to 30–40% in patients with developmen‐
tal delay/intellectual disability (DD/ID) or ASD, describing numerous genetic alterations. 
Overall, identified genetic causes of autism can be classified as single‐gene disorders (5%), 
cytogenetically visible chromosomal abnormalities (5%), and copy number variants (CNV) 
(10–20%) [26].
Chromosomal microarray analysis (CMA) is increasingly utilized for genetic testing of indi‐
viduals with unexplained DD/ID, multiple congenital anomalies (MCA), and has become 
increasingly important in the assessment of patients’ ASD. CMA was initially restricted to 
ASD patients with specific additional phenotypic characteristics or comorbidities (DD/ID or 
MCA); at present, it has been established as the general recommendation and consensus state‐
ment that CMA should be offered as a first‐tier diagnostic test in the assessment of patients 
with ASD in place of G‐banded karyotyping [27]. Since CMA is higher (8.9%) than conven‐
tional karyotyping (1.6%) and other genetic analyses (3.8%) they are changing the frequency 
of the causes of ASD [28].
CNV is the most prevalent type of structural variation in the human genome [29] and they 
have been described as having strong association of “de novo” CNV with autism [30]. So, at 
least 8% of sporadic ASD cases carried a de novo CNV and they are clarifying the etiology 
for many cases of autism previously considered idiopathic [31, 32]. The de novo nature of 
these CNVs, together with their absence in the general population, suggests they repre‐
sent a class of highly deleterious and highly penetrant mutations. Smaller microdeletions 
or microduplications may occur within this highly dynamic with frequent rearrangements 
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using alternative low‐copy repeats (LCRs), also known as segmental duplications (SDs), as 
recombination substrates during nonallelic homologous recombination (NAHR).
The presence of these sequences in LCRs concentrated on “hotspots,” in recurring break 
points, it confers great instability, with frequent deletions, duplications, and the formation 
of small chromosome markers, since these repeated sequences can lead to incorrect mei‐
otic recombination by NAHR and can be interchromosomal (between homologous chro‐
mosomes) or intrachromosomal (in the same chromosome); and every day are described 
new loci for recurrent NAHR‐mediated CNV [33]. Specially “recurrent microdeletions” in 
ASD include: 22q13 deletion or Phelan‐McDermid syndrome, 15q13.2‐q13.3 (BP4–BP5) dele‐
tion, 16p11.2 deletion syndrome, 17q12 deletion. And “recurrent microduplications” like: 
duplication of 15q11‐q13 or Dup15q syndrome in Prader Willi/Angelman region; duplication 
7q11.23 in Williams's syndrome region; duplication of 22q11.2 in DiGeorge syndrome region 
(for review see [34]). Some of the genes contained within the de novo CNVs we identified 
are good candidates for autism [35]. Although specific “rare de novo” CNVs are individually 
infrequent, but combined they account for a significant fraction of patients with autism and 
their study could contribute to a better understanding of the phenotypic manifestations in 
ASD [36, 37].
We want to highlight as Phelan‐McDermid syndrome (22q13.3 deletion syndrome) with a dis‐
ruption of the SHANK3 gene, it is believed to be underdiagnosed due to lack of specific clini‐
cal features, and because until recently it has inadequate genetic testing [38]. So when ASD is 
associated with intellectual disability, SHANK3 mutations or deletions have been found in up 
to 2.3% of cases of ASD individuals [39].
The region 15q11 contains a number of LCRs (regions of repetitive DNA which are sus‐
ceptible to rearrangements) known as breakpoint (bp) bp1, bp2, bp3, bp4, and bp5; and 
is especially linked to autism. The 15q11.2 BP1‐BP2 microdeletion is emerging as a recog‐
nized new syndrome, its appearance ranging from 0.57 to 1.27% of patients sent for microar‐
ray analysis. Its expression can be variable: patients may present with developmental and 
language delay, neurobehavioral disturbances, and ASD in 27% of patients. The BP1‐BP2 
region include four genes (TUBGCP5, CYFIP1, NIPA1, and NIPA2) which are not subject to 
imprinting (a differential expression depending on maternal or paternal origin gene) and 
therefore with expression biallelicis [40]. Larger deletions involving BP3 (BP1‐BP3 and BP2‐
BP3) cause either Prader‐Willi or Angelman syndrome (PWS/AS) depending on which par‐
ent the deleted chromosome is inherited from (paternal or maternal, respectively). And also 
worth noting is duplications of the chromosome 15q11‐q13.1 region (Dup15q syndrome) 
typically of maternal origin, which are associated with an estimated 1–3% of all autism 
cases, making this CNV one of the most frequent chromosome abnormalities associated 
with ASD. The region including ubiquitin protein ligase E3A (UBE3A)—the gene disrupted 
in Angelman syndrome—is involved in neural function and may play important roles in 
the neurobehavioral phenotypes associated with Dup15q syndrome. Genome‐wide analy‐
ses suggest that common neuronal pathways may be disrupted in both the AS and Dup15q 
syndromes [31].
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3.2. Genetic factors in ASD “nonsyndromic or idiopathic”
The concordance remarkably from 60 to 92% in monozygotic twins and from 0 to 10% in 
dizygotic pairs suggests a strong genetic component [41, 42]. Nevertheless, the recurrence 
rate of ADS in siblings of affected children is approximately 2% [43], which is 16 times higher 
than in the general population but much lower than in single‐gene diseases, so the underlying 
genetic determinants are still largely unknown [41]. Recent advances in genetic screening (as 
next‐generation sequencing, NGS, and whole‐exome sequencing, WES) and systems biology 
approaches have extended our knowledge of the genetic etiology of ASD, and may lead to the 
discovery of underlying genetic factors for ASD, and may thereby identify novel therapeutic 
targets for this disorder [35].
3.2.1. Linkage and candidate gene association studies
During the past decade, research about the genetic variations that underlie susceptibility to 
ASD has been focusing on linkage and candidate gene studies. Even though genetics is con‐
sidered to play a significant role in ASD, until recently solely 16–17% of autistics are car‐
riers of a known genetic variant. A large number of linkage studies have been conducted 
and have identified possible susceptibility loci on multiple chromosomes. Although there is 
no full agreement among different studies, certain regions, such as those on chromosomes 
2q, 3, 7q, 11, 16, 17q, and 19, have been involved in multiple occasions (for review see [44]), 
but only few common alterations were recognized as candidate genes in association studies 
including support from meta‐analysis [45, 46]. So, only a few loci show recurrent mutations 
(particularly the 7q22‐q37 and the 11p12‐p13 locus) [47, 48], and these “recurrent mutations” 
account for only about 1–2% of patients [49]. The studies have identified several ASD candi‐
dates including genes encoding neuroligins [50], neurexins [47], or SHANK3 [51].
This is now changing, linkage data with WES data has achieved great success for identifying 
many Mendelian disease genes [52–55] and the number of such studies is increasing gradu‐
ally (for review see [35]). Studies carried out in twins, in which one sibling had a diagnosis of 
autism and the other was not affected, bioinformatics and gene ontological analyses implicate 
genes which are involved in nervous system development, inflammation, and cytoskeletal 
organization, in addition to genes which may be relevant to gastrointestinal or other physi‐
ological symptoms often associated with autism; and these processes may be modulated by 
cholesterol/steroid metabolism, especially at the level of androgenic hormones (higher levels 
of testosterone in the autistic sibling) [56].
3.2.2. Genome‐wide association studies (GWAS)
The genetic architecture of ASD comprises a diversity of rare single nucleotide variants 
(SNVs), copy number variations (CNVs), chromosomal abnormalities, and common poly‐
morphic variations [57–59]. Genome‐wide association study (GWAS) is an examination of 
a genome‐wide set of genetics variants in different individuals to see if any variant is asso‐
ciated with a trait. Advances in genomic technology, including GWAS of single nucleotide 
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polymorphisms (SNPs), and CNV studies, allow the detection of de novo or inherited muta‐
tions in the coding regions and new candidate genes for ASD. Principally, CNVs implicate 
many ASD‐associated genes like CHD2, HDAC4, GDI1 SETD5, MIR137, HDAC9, SHANK2, 
SYNGAP1, DLGAP2, and the X‐linked DDX53‐PTCHD1 locus [60, 61]. But this only represents 
a selected sample of examples of the numerous studies in this field; inasmuch as these CNVs 
are widely distributed across the genome, at more than 100 different loci. The statistical distri‐
bution of influences across the genome suggests that hundreds of different human genes can 
mutate to influence autism risk [53]. Also, there is recent interest in rare highly penetrant SNV 
analogous to these traditional genetic models that may influence risk for “idiopathic autism.” 
SNVs most commonly identified in ASD cohort including among others: NRXN1, SHANK3, 
CTNNA3, CHD8, SCN1A and 2A, ADNP, PTEN, DYRK1A, and SYNGAP1 [52, 53, 55, 62, 63]. 
Genes affected by de novo CNVs and/or loss‐of‐function SNVs converged on networks related 
to neuronal signaling and development, synapse function, and chromatin regulation [61].
Up to now, estimates suggest that CNVs and SNVs acting in dominant, recessive, or X‐linked 
models might account for a small proportion of ASD (as many as 15% of cases), and common 
SNP can account for nearly half the variation in autism. Several GWASs [61, 64–66] have been 
performed to decipher the genetic etiology of autism that is attributable to common variants 
(i.e., SNPs) with only a few variants having shown significant associations and replicated in 
an independent population or in endophenotypes. Based on results from individual SNPs 
and their en masse effect on risk, as inferred from the allele score results, it is reasonable to 
conclude that common variants affect the risk for ASD but their individual effects are modest.
3.2.3. Molecular pathways ASD: “developmental synaptopathies”
As it has been mentioned previously, recent advancements in NGS and WES have enabled the 
discovery of an overwhelming number of de novo mutations (from 500 to 1000 genes) distrib‐
uted along all chromosomes that confer a risk for ASD demonstrating a heterogeneous genetic 
landscape [35]. For an up‐to‐date database of ASD‐associated genes, the reader is referred to 
the SFARI Gene database (Simons Foundation Autism Research Initiative; https://gene.sfari.
org/). As of June 2016, there were 826 genes and 2163 CNV loci in this database. This resource 
reviews the evidence for each gene implicated in autism susceptibility and assigns a score, 
from “Category 1” (“high confidence,” with 16 listed: ADNP, ANK2, ARID1B, ASH1L, ASXL3, 
CHD8, DYRK1A, GRIN2B, POGZ, PTEN, SCN2A, SETD5, SHANK3, SUV420H1, SYNGAP1, 
and TBR1 genes), to “Category 6” (“not supported”). Genes associated with syndromic ASD 
are categorized separately (“Category S,” including 78 genes, among the best known are: 
FMR1 cause Fragile X syndrome, MECP2 cause Rett syndrome, SHANK3 is part of a mul‐
tigenic region that is deleted in Phelan‐McDermid syndrome, UBE3A present in common 
15q11‐13 duplications syndrome or deletion in Angelman syndrome, RERE in 1p36 deletion 
syndrome, PTEN in Cowden syndrome, etc.).
Fortunately, although the ADS‐risk genes are numerous, and many of them have a dual func‐
tion involved in different neural networks, they seem to converge in a limited number of 
molecular pathways [67], allowing the study from single gene to a pathway perspective [68]. 
So, it has been proposed that, rather than as a result of dysfunction of specific genes, ASD 
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result in dysfunction of specific genetic pathways [69]. The identified several potential genetic 
pathways to ASD including wnt signaling during development, synaptic function, chroma‐
tin remodeling, mRNA translation, and metabolism seem to converge in common functional 
pathways affecting neuronal and synaptic homeostasis [70]. Just like that, 88% of high‐risk 
genes for autism influence neural induction and early maturation of the neuroblast. In addi‐
tion, 80% of these same genes influence later stages of differentiation, including neurite and 
synapse development [71].
Rare mutations‐ASD include mutations in synaptic proteins such as ProSAPs/SHANKS pro‐
teins (with a crucial role in the assembly of the postsynaptic density during synaptogenesis, 
in synaptic plasticity and in the regulation of dendritic spine morphology) [72–74]; synaptic 
vesicle‐associated proteins (SYN2 gene) [75]; and neuroligins/neurexins (synaptic cell adhe‐
sion molecules) for excitatory glutamatergic and inhibitory GABAergic synapses [neurexins 
(NRXN) (trigger postsynaptic differentiation), and neuroligins (NLGN) (trigger presynaptic 
differentiation)] [76] and play a pivotal role in synaptic function, especially at GABAergic 
synapses [77]. It has been shown that many genes associated with ASDs are involved in the 
neuroligin‐neurexin interaction at the glutamate synapse: NLGN3, and NLGN4 on the X chro‐
mosome [50, 78, 79], NRXN1 on chromosome 2p16 [80], CNTNAP2 on chromosome 7q35 [81], 
and SHANK3 on chromosome 22q13 [51, 82]. Autism‐associated NLGN3 mutations commonly 
disrupt tonic endocannabinoid signaling, providing evidence that alterations in the endocan‐
nabinoid pathway may contribute to autism pathophysiology [83]. Besides the neurotrophic 
factors as well as the neurotransmitter systems are thought to be good candidates for ASD 
[84]. Thereby, elevated platelet serotonin (5‐HT) in 20–25% of ASD cases points to the 5‐HT 
transporter (5‐HTT; SERT) as a strong candidate gene, and also allelic heterogeneity at sero‐
tonin transporter locus (SLC6A4) may be connected with susceptibility to autism [85]. Also, 
it has been implicated in the catecholaminergic pathways (allelic variants in the dopamine 
decarboxylase (DDC) gene) [86].
It has been proposed that genes involved in “monogenic” forms of syndromic and nonsyn‐
dromic ASD converge on common molecular pathways and mechanisms of synaptic dysfunc‐
tion (“developmental synaptopathies”): control synaptic protein synthesis and degradation 
with postsynaptic scaffold architecture and neurotransmitter receptors; and that are involved 
in synaptic development, plasticity, and signaling [87]. Many studies have suggested that 
neurites and synapses associated gene products, in fact, may be involved in the early stages of 
neural differentiation normally recognized, resulting in defects of migration and other indica‐
tions of disturbance to premigratory cell fate determination [88–90].
However, it is yet unclear whether the same genes may performance through rare, highly pene‐
trant mutations and common genetic risk factors. Additionally, although many approaches have 
attempted to identify “molecular pathways” implicated in ASDs to unify disparate genes, these 
data have not converged to provide conclusive and well‐replicated evidence. How these muta‐
tions lead to ASD phenotypes is poorly understood (for review see [91, 92]). Hence, most cases 
still remain unknown, but potentially, including additional less penetrant rare variants or com‐
plex mechanisms, such as gene‐gene interaction or gene‐environment interaction. In this way, 
one might conclude that interactions between multiple genes cause “idiopathic” autism, but that 
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“epigenetic dysregulation” and exposure to environmental modifiers might contribute to vari‐
able expression of autism‐related traits [93] and to significant proportion of ASD cases [94–96].
4. Epigenetic and chromatin structure
Definition: Epigenetics is an important aspect of research in current biology, defined as the 
study of mitotically and meiotically heritable changes in gene function that are not dependent 
on DNA sequence [97]. So “an epigenetic trait is a stably heritable phenotype resulting from 
changes in a chromosome without alterations in the DNA sequence.” Epigenetics shows that 
gene expression undergoes changes more complex than modifications in the DNA sequence; 
it includes the influence of the environment on the gametes prior to conception. Berger et al. 
[98] proposed three categories of signals that culminate in the establishment of a stably heri‐
table epigenetic state:
• A signal that we propose to call the “Epigenator,” which emanates from the environment 
and triggers an intracellular pathway.
• An “Epigenetic Initiator” signal, which responds to the Epigenator and is necessary to 
define the precise location of the epigenetic chromatin environment. The Initiator could be 
a DNA‐binding protein, a noncoding RNA, or any other entity that can define the coordi‐
nates of the chromatin structure to be assembled.
• An “Epigenetic Maintainer” signal, which sustains the chromatin environment in the first 
and subsequent generations.
The molecular basis of epigenetic processes: is complex and this signal involves many dif‐
ferent mechanisms, including major epigenetic silencing pathways: DNA methylation, modi‐
fications (like methylation and acetylation) of histones (H), positioning of histone variants, 
and gene regulation by small noncoding RNAs [99].
The study of chromatin structure has taken an important impetus in recent years and has tran‐
scended to the point to understand various diseases in humans including ASD. Chromatin is 
the structure in which the DNA is organized and packed into the nucleus of the eukaryotic 
cell. The main components of chromatin are DNA and histone proteins; both units are the tar‐
get of epigenetic modifications. The primary unit is the nucleosome, formed for a segment of 
DNA (approximately 200 base pairs) wound in sequence around eight histone protein cores 
(H2A, H2B, H3, and H4), and linker subunit H1 that connects the nucleosomes. A region of 
chromatin is in a more or less favorable to gene expression depending on the type of sequences 
that form and also epigenetic modifications at that level state. The regulation mechanism of 
transcriptional activity is mainly mediated by DNA methylation and chromatin remodeling.
DNA methylation: Methylation of DNA and mainly 5‐methylcytosine methylation is a major 
mechanism of epigenetic gene silencing, essential for cell division and normal development, 
and plays an important role of key processes including inactivation of the X‐chromosome, 
genomic imprinting, gene silencing, and repression of repetitive elements. DNA methylation 
may affect the transcription of genes in two ways:
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• Directly impede the binding of transcriptional proteins to the gene.
• Methylated DNA may be bound by proteins known as methyl‐CpG‐binding domain pro‐
teins (MBDs) which later recruit additional proteins to the locus, such as histone deacety‐
lases (HDAC) and other chromatin remodeling proteins that can modify histones, thereby 
forming heterochromatin.
Chromatin remodeling: Modulate chromatin structure and function can involve covalent 
modification of histones (acetylation, methylation, or ubiquitination of lysine; methylation of 
arginine; and phosphorylation of serine), the incorporation of histone variants, and noncova‐
lent ATP‐dependent chromatin remodeling complexes. One of the most significant epigenetic 
processes is to strengthen or weaken the interactions between DNA and histones (“histone 
code” as epigenetic histone chemical modifications in nucleosomes). The regulation of each 
histone modification requires specific enzymes that add or remove the methyl or acetyl 
group. The histone modifications affect interactions between nucleosomes and therefore the 
degree of chromatin condensation, so a region will behave as euchromatin, lightly packed, 
and accessible to active transcription; or in reverse when the interaction is strong, the his‐
tones are attached firmly to the DNA chromatin (heterochromatin), this means in a closed 
or dormant state, and it is tightly packed and inaccessible to polymerases and therefore not 
transcribed [100].
In the transition from the closed conformation to a more open chromatin, the interactions 
between histones and DNA must be dissolved. This process requires epigenetic “writer” as 
transferases that add specific small molecules such as the methyl and acetyl groups to DNA, 
or proteins to alter its pack aging proteins—the histones—such as histone acetyltransferases 
(HATs), histone methyltransferases (HMTs), protein arginine methyltransferases (PRMTs), 
and kinases lay down epigenetic marks on amino acid residues on histone tails. This modifi‐
cation (e.g., by adding an acetyl group) blocks the ability of the histone to bind DNA and thus 
making the chromatin more open and is associated with active gene expression. In contrast, 
epigenetic “eraser” proteins, such as histone deacetylases (HDACs), lysine demethylases 
(KDMs), and phosphatases catalyse, remove the epigenetic marks from the histones restor‐
ing the interaction between the histone and DNA, leaving the DNA once again in a closed 
conformation tends to be present in transcriptionally silent regions. The epigenetic “readers” 
(such as proteins containing bromodomains, chromodomains, and Tudor domains) are tran‐
scriptional regulators proteins that do not alter the histone but rather detect the acetyl group 
within the histones.
Proteins that contain reader domains can be usually classified into four groups: chroma‐
tin architectural proteins (induce chromatin compaction), chromatin remodeling enzymes 
(prompt a more open chromatin architecture driven by the energy of ATP hydrolysis), chro‐
matin modifiers, and adaptor proteins that recruit other machinery involved in gene expres‐
sion. Enzymes which “write” or “erase” epigenetic marks may also contain such reader 
domains, leading to the coordination of “read‐write” or “read‐erase” epigenetic processes 
[101]. The proper gene expression requires the attainment of a balance between the activities 
of the two opposing systems (writers and erasers) and subsequently the placement of their 
respective marks, which ensures that the appropriate composition of chromatin is present at 
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particular gene promoters. Opposite histone systems are susceptible to be dynamic, allowing 
the cell to quickly respond to changes in environmental signals by altering gene expression at 
specific loci. Epigenetic machinery is highly redundant, perhaps reflecting the critical impor‐
tance of maintaining this balance in many different cell types
5. Epigenetic changes involved in ASD
As we mentioned previously, the rates of ADS diagnosis have dramatically increased in the 
past three decades to constitute “autism epidemic” and have been well documented in public 
health surveillance studies [102]. New advances in genetic studies (Linkage and candidate gene 
association studies and GWAS) identifying multifarious loci associated with ASD, especially 
mutations in genes encoding synapse‐associated proteins (Shank/ProSAP proteins, synap‐
tic vesicle‐associated proteins, synaptic cell adhesion molecules, neurotransmitter…); how‐
ever so far, genetic analyses have mainly been on the ~1.5% of the genome encoding genes. 
Although genetic contributions to autism etiology are well accepted, genetics alone does not 
explain the underlying cause in a substantial proportion of cases. So, the rising prevalence and 
inconsistent finding from genetic studies suggest a role for interactions between susceptibility 
genes and relevance of environmental factors and other potential contributors. Now there is 
convincing evidence that gene interactions with the environment are important in the etiol‐
ogy of ASD. However, the mechanisms by which environmental factors interact with genetic 
susceptibilities to confer individual risk for ASD remain significant knowledge emptiness in 
the field. It has been suggested that environmental factors linked to epigenetic mechanisms 
as DNA methylation and/or histone modifications; they may be involved in ASD by changes 
into the function of the genome.
A number of rare Mendelian disorders, such as Rett syndrome (by mutation in MECP2, locus 
Xq28), Cornelia de Lange syndrome‐2 (by mutations of the SMC1A gene locus Xp11.2 encodes 
a subunit of the cohesin complex, essential for sister chromatid cohesion during mitosis, with 
broad roles in chromosome condensation, and DNA repair), and Coffin‐Siris syndrome (chro‐
matin remodeling complex gene ARID1B which encodes an epigenetic modifier of chromatin 
structure) have pointed to the importance of DNA methylation and chromatin remodeling 
factors, mainly histones in human brain development. At present the identification of other 
ATP‐dependent chromatin remodelers (e.g., CHD8) and transcription factors (e.g., ADNP, 
ASH1L, FOXG1), which are also typically involved in regulation of gene expression but with‐
out alterations in the DNA sequence, have aroused the interest toward the epigenetics of 
autism and how environmental factors may be playing a key role in transcriptional regulatory 
influences [94–96, 103, 104].
Recent advances in genomic technologies allow a position to initiate large‐scale studies of 
human disease‐associated epigenetic variation, specifically variation in DNA methylation, 
and highlight the contribution of noncoding variants to the etiology of ASD. Epigenetic 
state in ASD, mainly epigenetic mark of DNA CpG methylation, can be used as biomarker 
of disease risk, diagnosis, prognosis, and response to treatments; but also, clues to the causal 
factors and mechanisms of the disorder [105]. So, aberrant methylation profiles in 1.1% of 
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ASD cases have been reported [13]. A significant overrepresentation of genes with functions 
in chromatin regulation and early developmental expression was found in ASD probands 
but not in unaffected siblings [106]. Also, oxidative protein/DNA damage and DNA hypo‐
methylation (epigenetic alteration) were found in autistic children but not paired siblings or 
controls [107]. So, nowadays attention has turned to environmental factors but also with epi‐
genetic changes as potential etiological agents predisposing to autism susceptibility. New 
genetics analyses have displayed a multitude of novel candidate ASD‐genes in networks 
that involve epigenetic change, encoding nuclear factors implicated in chromatin remodel‐
ing, histone demethylation, histone variants, and the recognition of DNA methylation [13, 
108]. This approach is described as an “epigenome‐wide association study” (EWAS) and 
takes its cue from the association of genetic variability with phenotypes in GWAS. However 
until today and in contradistinction to GWAS, EWAS are scarce related to ASD (for review 
see [109]).
Just like that functionally, ASD‐risk genes often converge in key molecular pathways early 
in development, which modulate synaptic transmission but also chromatin remodeling and 
transcriptional regulation, allowing to define autism as “synaptic and chromatin‐remod‐
eling disorders” [110]. All of the above can be added to state that epigenetic changes are 
potentially reversible, and, therefore, a thorough understanding of these modifications may 
identify new therapeutic targets for the disease. So finally the question arises: Is autism 
also an acquired and therefore preventable, treatable, and potentially curable epigenetic 
disease?
Epigenetic studies besides being keys to the causal factors, also clues to the biomarkers and 
physiological mechanisms predisposing or resulting from the onset of ASD, and may have an 
important role in the therapeutic implications. So this chapter will focus on developing the 
main aspects related to epigenetics of autism, according to the following scheme:
• Congenital epigenetic diseases in ASD:
 ○ Imprinted‐x liability. Sex differences.
 ○ Classical imprinting disorders.
 ○ Mendelian ASD disorders of the epigenetic machinery:
 ▪ Mendelian ASD disorders in DNA methylation machinery.
 ▪ Mendelian ASD disorders in the histone machinery.
 ▪ Mendelian ASD disorders in other chromatin remodelers and transcription factors.
• Acquired epigenetics disorders in ASD.
6. Congenital epigenetic diseases in ASD
Congenital epigenetic diseases are a newly delineated group of multiple congenital anoma‐
lies, intellectual disabilities, and ASD syndromes resulting from:
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• Classic epigenetic processes: X chromosome inactivation and genomic imprinting are clas‐
sic epigenetic processes that cause disease when not appropriately regulated. “Classical 
imprinting disorders” or epigenetic alterations at specific loci result mainly from disrup‐
tions occurring in cis (acting in cis).
• “Mendelian disorders of the epigenetic machinery” or mutations in genes encoding com‐
ponents of the DNA methylation machinery and histone modifications machinery, which 
implicate trans‐acting factors (acting in trans), and are thus expected to have widespread 
downstream epigenetic consequences (for review see [111–113]).
6.1. The imprinted‐X liability: sex differences
X chromosome inactivation (XCI) evolved to solve the problem of gene dosage compensa‐
tion between XY males and XX females by random inactivation of one of the two female X 
chromosomes in placental mammals. X inactivation is controlled by a single X‐linked cis‐act‐
ing locus called the X inactivation center (Xic), which contains the noncoding RNA encoding 
X‐inactive specific transcript (Xist) locus. However, there are regions on the XCI that sustain 
active transcription and “escape” inactivation by looping out of the chromosomal territory 
covered by Xist.
The male predominance universally observed in ASD (male:female ratio approximately 4:1) 
is one of the best known, and at the same time, one of the least understood characteristics of 
these disorders. The mechanisms underlying this male preponderance have been associated 
with genetic, epigenetic, hormonal (e.g., early exposure to androgenic hormones), and envi‐
ronmental factors (e.g., prenatal stress, early maternal immune activation) [114]. It has been 
proposed that the pronounced sex ratio of ASD could be related to genetic loci expressed on 
the noninactivated X chromosome modulate the phenotypic expression of autosomal loci con‐
ferring risk for ASD [115]. Females have detectably lower global levels of DNA methylation, 
and increasing the number of X chromosomes further reduces the methylation on autosomes 
[116]. The mechanism of female protective effect is unknown, yet genome scans have not 
revealed any predisposing loci on the sex chromosomes [117]. It has been hypothesized as 
“the imprinted‐X liability threshold model,” so imprinted X‐linked gene(s) that is ASD pro‐
tective in nature and raises the threshold for phenotypic expression is expressed only in the X‐
chromosome inherited from the father. It is normally silenced when transmitted maternally, 
so because only females have a paternal X‐chromosome, the threshold for phenotypic expres‐
sion is higher in them than in males [118]. Evidence for the existence of the genetic locus was 
found in a study of females with Turner's syndrome (X‐monosomy), in which females had 
either a single paternal or maternal X‐chromosome [119].
The studies of sex differences in normal human brain development at the genomic level are 
lacking; a recent large transcriptomic study shows that male‐biased genes are enriched for 
pathways repeatedly implicated in autism like the processes of extracellular matrix forma‐
tion/glycoproteins, immune response, chromatin, and cell cytoskeleton [120]. X chromosome 
inactivation status in female human induced pluripotent stem cells (hiPSCs) and their dif‐
ferentiation into neurons have shown complexities. A small number of recent papers have 
begun to explore cellular phenotypes of autism observed in hiPSC‐derived neurons [121–123]. 
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However, at present there are major gaps and inconsistencies in the existing literature regard‐
ing XCI status during the derivation and maintenance of hiPSCs (for review see [124, 125]).
Moreover, not all genes on the inactive X chromosome are inactivated, and the genes that 
“escape” X inactivation in females are revealing some interesting ideas on chromatin and 
brain transcriptional sex differences in understanding the female protective effect in autism 
[126]. An example is X‐chromosome‐linked ichthyosis caused by mutation or deletion of the 
STS gene associated with a deficiency of the enzyme steroid sulphatase, located in the distal 
part of the short arm of the X chromosome (Xp22.3‐pter) and the importance of the region 
in the higher incidence of neurological disorders among males like attention deficit hyper‐
activity disorder, autism, and X‐linked mental retardation [127]. Other gene that escapes X 
chromosome inactivation is KDM5C locus Xp11.22, encoding O‐linked‐N‐acetylglucosamine 
(O‐GlcNAc) transferase (OGT) that regulates chromatin remodeling factors (histone demeth‐
ylase of H3K4, implicated in gene repression), is expressed lower in males than females and 
further reduced by prenatal stress [128].
6.2. Classical imprinting disorders
As X chromosome inactivation, gene‐imprinting process is a selective differential gene expres‐
sion regulated by epigenetic mechanisms that are different, but in this case, determined by 
the parental origin of the alleles. Human‐imprinting disorders are a group of eight rare but 
probably underdiagnosed congenital disorders of growth, development, and metabolism, 
and represent a curious defiance of normal Mendelian genetics. They are caused by similar 
molecular changes affecting regulation, dosage, or the genomic sequence of imprinted genes, 
associated with disturbance of parent of origin‐specific DNA methylation across the genome. 
Humans inherit two alleles from mother and father, both are functional for the majority of 
the genes, but sometimes one is turned off or “stamped” and does not show in offspring, that 
the gene is imprinted. The term imprinting refers to the differential expression of alleles (the 
repressed allele is methylated, while the active allele is unmethylated) for a particular gene 
depending on the parental origin of the allele. Each allele contains a distinct set of epigenetic 
modifications or marks, which influence chromatin structure and regulate gene expression at 
particular imprinted loci [129].
At present there are more than 200 genes subject to imprinting in humans, 97 demonstrated 
and 107 predicted, generally grouped into different chromosomal regions. For an up‐to‐date 
database of imprinted genes, the reader is referred to the Geneimprint database (Geneimprint 
database; http://www.geneimprint.com). Nevertheless, it remains to be identified the overall 
role of human imprinted genes and their regulatory elements implicated in the puzzle of 
ASD. The regulation of the differential expression of genes at imprinted loci is quite complex 
and involves DNA methylation, characteristic epigenetic signatures of associated covalent 
posttranslational modifications of histone tails, noncoding RNAs, and transacting factors, all 
of which play a key role in the process [130]. Epigenetic imbalances in the effects of imprinted 
genes has been associated with different abnormalities in development: Psychotic spectrum 
conditions (schizophrenia, bipolar disorder, major depression, PWS, Klinefelter syndrome) 
have been mediated in part by alterations of imprinted genes with maternal expression or 
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other genes favoring maternal interests. By contrast, ASD (like Kanner autism, Asperger syn‐
drome, Turner syndrome, AS, and Beckwith‐Wiedemann syndrome), commonly engender 
increased relative effects from paternally expressed imprinted genes, or reduced effects from 
genes favoring maternal interests [131].
Imprinting disorders may result by different genetic mechanisms: deletion of the critical 
region, paternal/maternal uniparental disomy (UPD), imprinting center defect, and mutation 
in the imprinting gene (for review see [132]). For most chromosomes, no obvious pheno‐
typic effect from UPD has been observed. However, UPD of certain chromosomes affecting 
imprinted region leads to clinically recognizable syndromes (e.g., UPD affecting the chromo‐
some 14q32.2 imprinted region is one that causes a distinct disorder: Temple syndrome (or 
maternal UPD) and Kagami‐Ogata syndrome (or paternal UPD), although different, are two 
sides of the same coin [133–135]).
The association of so‐called “classical imprinting diseases” and autism is well known. For 
example, imprinted gene locus on 15q11 region, results from the loss of function or overex‐
pression of at least 1 imprinted gene [136]. Prader‐Willi syndrome (PWS) is caused by a lack 
of the paternal contribution of genes, and Angelman syndrome (AS) is caused by a lack of 
maternal UBE3A expression resulting from disrupted imprinting via a variety of genetic and 
epigenetic mechanisms occurring in cis [137]. Duplication of 15q11‐q13: As we mentioned 
previously, microduplication of the 15q11‐q13 segment is the most consistently known chro‐
mosomal abnormality reported in ASD (1–3% of all autism cases), which occurred on the 
maternally derived chromosome. It represents a contiguous gene duplication syndrome, 
and reveals epigenetic alterations in gene expression. The segment contains a cluster of 
three GABA (A) receptor subunit (GABR) genes (imprinted key genes) essential for normal 
neurodevelopment [138]. Genome‐wide analyses suggest that common neuronal pathways 
can be disrupted in both the Angelman and Dup15q syndromes. mRNA‐Seq experiments 
show that there is substantial overlap of differentially expressed genes between 15q11‐q13.1 
deletion and duplication neurons. UBE3A transcripts can be pharmacologically rescued to 
normal levels in induced pluripotent stem cell (iPSC)‐derived neurons with 15q11‐q13.1 
duplication [139].
Another imprinted region 11p15 contains two separate imprinting domains: the IGF2/H19 
locus [imprinting control region 1 (ICR1)] and the CDKN1C/KCNQOT1 locus (ICR2). When 
either locus is disrupted, tipping the balance toward increased expression of paternal genes, 
the Beckwith‐Wiedemann syndrome (BWS) overgrowth disorder occurs. This dosage imbal‐
ance occurs primarily via epigenetic mechanisms acting in cis, most commonly loss of meth‐
ylation at ICR2, gain of methylation at ICR1, or paternal uniparental disomy (UPD) of the 
entire 11p15 region [140]. In BWS 6.8% of patients had been diagnosed of ASD, and occurred 
in children with UPD and ICR2 defects [141]. By contrast, Russell‐Silver syndrome (RSS) with 
growth failure can result from paternal hypomethylation at ICR1, a gene dosage imbalance 
that leads to increased maternal gene expression with no paternal contribution [142].
We highlighted as BWS and AS occur with an increased incidence in the offspring of infertile 
couples conceived following assisted reproductive technologies, which involve a multitude 
of environmental disruptions that could potentially impact malleable epigenetic marks [143]. 
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However, earlier investigations on possible links between artificial reproductive technologies 
and autism have shown inconsistent findings [144, 145]. More recent epidemiological studies 
involving larger populations display that IVF is not associated with ASD [146]; but the risk for 
autism is associated with a small increased risk of intellectual disability, and was significantly 
higher following intracytoplasmic spermatozoid injection (ICSI) using surgically extracted 
sperm and fresh embryos compared to in vitro fertilization (IVF) without ICSI [147].
6.3. Mendelian ASD disorders of the “epigenetic machinery”
Mendelian disorders of the epigenetic machinery are a newly delineated group of multiple 
congenital anomaly, intellectual disability, and autism syndromes arising from mutations in 
genes encoding components of the chromatin remodeling epigenetic pathways.
6.3.1. Mendelian ASD disorders in DNA methylation machinery
• Rett syndrome (RTT) is an X‐linked dominant (Xq28) and severe neurological disorder 
caused by mutations in the gene that encode a single polypeptide MeCP2 (methyl‐CpG‐
binding protein 2), a chromatin‐associated protein [148] that contains both a methyl‐CpG 
binding domain (MBD) and transcriptional repression domain (TRD) associated with the 
regulation of gene expression by activating or repressing transcription, or by functioning 
at a posttranscriptional level. MeCP2 is capable of binding specifically to methylated DNA 
and form a complex with histone deacetylase (HDAC/Sin3A complex). MeCP2‐mediated 
transcriptional repression may involve two distinct mechanisms one being dependent on 
chromatin modification by histone deacetylation and the other being chromatin indepen‐
dent (block transcription factors directly) [149–151]. In RTT patients’ lymphocytes com‐
pared with controls have been shown to be increased in the density of histone H3, and 
decreased levels of trimethylation of lysine 4 on histone H3 (H3K4me3), a modification 
associated with transcriptional activation [152]. MeCP2 results in the alteration of the chro‐
matin state by suppressing a number of target genes associated with synaptic function and 
disrupted synaptic plasticity mechanisms (e.g., BDNF, DLX5, ID, CRH, IGFBP3, CDKL1, 
PCDHB1, and PCDH7, LIN7A) in neurons and other types of brain cells [153, 154]. Thereby 
controlling excitatory synaptic strength by regulating the number of glutamatergic syn‐
apse number [155].
• Fragile X syndrome (FXS, OMIM #300624) is the most common known genetic cause of 
inherited intellectual disability. Despite early controversy, it is now accepted that a sub‐
stantial proportion (50–75%) of children with FXS meets diagnostic criteria for ASD [156]. 
FXS is associated with a fragile site at Xq27.3, results from a repeat expansion mutation 
near the FMR1 (X‐linked gene fragile X mental retardation 1) gene promoter. Full muta‐
tions larger than 200 CGG repeats in the 5'UTR (5’ untranslated region) of the FMR1 are 
able to trigger FMR1 subsequent heterochromatinization by DNA methylation of the 
promoter region [157, 158], accompanied by additional epigenetic histone modifications 
(as DNA hypermethylation coupled with histone H3 and H4 tail deacetylation, and tri‐
methylation at critical residues H3K9 and H3K27) that result in a block of transcription in 
FMR1 and absence of the fragile X mental retardation protein (FMRP), involved in multiple 
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aspects of mRNA metabolism in the brain. Future studies could investigate a therapeutic 
approach to FXS based on the pharmacological reactivation of the FMR1 expression [159].
• MBD5 (methyl‐CpG‐binding domain 5) is an important factor in methylation pattern‐
ing and epigenetic regulation and key on the autistic spectrum. Although it was known 
that the loss of one copy of this gene is the major causative factor in 2q23.1 microdeletion 
syndrome and point mutations are associated with autism and intellectual disability [160, 
161], the duplication of this gene also causes disorders similar to those described in cases 
with abnormal loss of gene function development [162].
• Methylation level of specific genes in nonsyndromic ASD: The postmortem brain tissues 
from ASD patients show increased DNA methylation within the genes of: oxytocin recep‐
tor (OXTR) [163], RORA [164], Engrailed‐2 (EN2) homeobox gene [165], Reelin (RELN) 
[166], and BCL2 gene [167].
 ○ Oxytocin receptor (OXTR) is a G‐protein coupled receptor for the peptide hormone and 
neurotransmitter oxytocin that activates the frontal cortex. OXTR is known to be involved 
in modeling human social behavior (social memory and recognition, anxiety, sexual and 
aggressive behaviors, and maternal‐offspring bonding), and a potential role of the “proso‐
cial” hormone in autism [168]. The involvement of this gene was suggested by its deletion 
in an autistic patient. The subsequent analysis of a group of unrelated autistic subjects did 
not show an OXTR deletion, but rather hypermethylation of the gene promoter, with a re‐
duced mRNA expression [163]. These findings address two major points of the current de‐
bate on the etiology and pathogenesis of autism: the role of the oxytocin‐vasopressin path‐
way and the possible social processes under epigenetic control. Several studies have begun 
to explore the so‐called OXT deficit hypothesis of ASD, but they have yielded conflicting 
results. Dysregulated OXT biology is not uniquely associated with ASD social phenotypes 
as widely theorized, but instead variation in OXT biology contributes to important indi‐
vidual differences in human social functioning, including the severe social impairments, 
which characterize ASD [169].
 ○ RORA (retinoic acid‐related orphan receptor alpha) is a proposed risk factor for autism 
because it is reduced in the brain and lymphoblastoid cell lines of multiple cohorts of in‐
dividuals with ASD, and oppositely regulated by male and female hormones. RORA and 
several of its transcriptional targets might contribute to the sex bias in autism by differ‐
entially regulating target genes, including CYP19A1 (aromatase) in certain regions of the 
brain of both mice and humans; in a sex‐dependent manner that can also lead to elevated 
testosterone levels. An important sex‐dependent difference has been found in the level of 
RORA protein in brain tissues of males and females. Specifically, females without autism 
have a slightly higher level of RORA in the frontal cortex of the brain than males without 
autism, while the levels of the protein are comparably lower in the brain of both males 
and females with autism. RORA‐deficient males may experience greater dysregulation of 
genes relevant to ASD in certain brain regions during development [164].
 ○ Engrailed‐2 (EN2) homeobox gene: contributes to neurodevelopmental disorders, espe‐
cially ASD. En2 knockout mice (En2‐/‐) display subtle cerebellar neuropathological chang‐
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es and reduced levels of tyrosine hydroxylase, noradrenaline, and serotonin in the hip‐
pocampus and cerebral cortex similar to those ones which have been observed in the ASD 
brain [170]. The disruption of hindbrain patterning genes can alter monoamine system 
development and thereby produce forebrain defects that are relevant to human neurode‐
velopmental disorders [171].
 ○ Others: In addition, significant correlations were also identified between the severity of the 
autistic phenotype and differential DNA methylation at several multiple loci implicated in 
the pathogenesis of ASDs. Genes that control synaptic molecules are subjected to a specific 
epigenetic control mechanism, for example, DNA methylation regulates the tissue‐specific 
expression of SHANK3 gene [172]. Other prominent genes regulated by epigenetic mecha‐
nisms include AFF2, APC, ARHGAP15, AUTS2, JMJD1C, GABRB3, KCNJ10 MAP2, MBD4, 
NLGN3, NRXN1, PIK3C3, SNRPN, SLC6A4, THAP10, TSNAX, and UBE3A [173].
6.3.2. Mendelian ASD disorders in the histone machinery
• Histone modifications include acetylation, methylation, ubiquitylation, phosphorylation, 
sumoylation, ribosylation, and citrullination. Histone lysine acetylation and histone lysine 
methylation are the most highly studied of these modifications. But histone demethylases 
are now emerging as important players in developmental processes and have been linked 
to human diseases such as neurological disorders and cancer.
 ○ Histone acetylation
Brain‐derived neurotrophic factor (BDNF) is a protein encoded by the BDNF gene local‐
ized to 11p13, whose transcription is controlled by eight different promoters and activity is 
strongly stimulated by calcium. BDNF is a prosurvival factor induced by cortical neurons that 
centrally mediates growth, differentiation, and survival of neurons, and essential to promote 
synaptic plasticity that underlies learning and persistence of long‐term memory storage [174]. 
BDNF binds at least two receptors on the surface of cells: TrkB and LNGFR. It may also modu‐
late the activity of various neurotransmitter receptors, like in serotonergic neurons. Histone 
modulation of BDNF particularly increased H3 acetylation at the BDNF gene in the medial 
prefrontal cortex (mPFC), and may be one of the molecular mechanisms that mediated the 
cognitive dysfunction [175]. Accumulating evidence suggests that BDNF may be implicated 
in the developmental outcomes of children with ASD. Three recent meta‐analysis show as 
children with ASD have increased peripheral blood levels of BDNF, strengthening the clini‐
cal evidence of an abnormal neurotrophic factor profile in this population. Peripheral BDNF 
levels are a potential biomarker of ASD [176–178].
Proteins involved in the “readout” of lysine acetylation marks, referred to as BET bromodo‐
main proteins (including BRD2, BRD3, BRD4, and BRDT), have been shown to be key regu‐
lators of chromatin dynamics and disease, and BET inhibitors are currently being studied in 
several clinical trials. Pharmacological suppression of BET proteins in the brain of young mice, 
by the novel, highly specific, brain‐permeable inhibitor I‐BET858 leads to selective suppres‐
sion of neuronal gene expression followed by the development of an autism‐like syndrome. 
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So, environmental factors controlling BET proteins or their target genes may contribute to the 
epigenetic mechanism of ASD [179].
 ○ Histone methylation
Recent large‐scale exome sequencing studies highlighted dysregulation of histone methyla‐
tion as a major contributing factor of ASD [180, 108]. Methylation of lysine 4 of histone H3 
(H3K4me) is one such modification, which is associated with gene activation. Two fami‐
lies of proteins serve as primary regulators of H3K4me: histone lysine methyltransferases 
(KMTs) are the “writers,” which place the methyl marks onto histones; and histone lysine 
demethylases (KDMs) are the “erasers,” which remove them. The mutations in histone lysine 
methyltransferase KMT2D are a major cause of Kabuki syndrome. Dysregulation of histone 
methyltransferases and histone deacetylases (HDACs) associated with low activity of methyl 
CpG binding protein‐2 at cytosine‐guanine sites in genes may reduce the capacity for con‐
densing chromatin and silencing genes in the frontal cortex, a site characterized by decreased 
cortical interconnectivity in autistic subjects (for review of mechanisms for altering DNA‐his‐
tone interactions see [181]).
To date, several genes were found mutated in autism encode histone methylation enzymes 
such as:
 − Methyltransferase complex genes: KMT2A, KMT2C, KMT2D, KMT2F encodes H3K4 meth‐
yltransferase [182]. EHMT1, EHTM2, and WIZ encode H3K9 methyltransferase [183]. 
Histone methyltransferase Ash1L mediates activity‐dependent repression of neurexin‐1α 
[184].
 − Histone demethylases: KDM5C encodes an H3K4‐specific eraser enzyme that directly 
catalyzes the demethylation of mono‐, di‐, and tri‐methylated H3K4, implicated in gene 
repression; and JMJD1C, a demethylase for histone H3K9 implicated in hormone‐depen‐
dent transcriptional activation.
• Histone variants: Macrohistones (mH) are unusual histone variants found exclusively in 
vertebrate chromatin.
 ○ The histone H2A subunit has a variant ‐macroH2A1.1 encoded by the autosomal gene 
H2AFY. The macroH2A1.1 is generally associated with repressed chromatin, such as the 
inactive X chromosome [185] and could explain the 4:1 male:female gender distortion pres‐
ent in autism. But because it also contains binding sites for cellular metabolites in through 
the macrodomain, macroH2A1.1 may have a more dynamic role in the modulation of gene 
expression in response to environmental signals [186]. Although macroH2A1.1 was identi‐
fied as an autism candidate gene by a GWAS, no association was found [187].
 ○ A related family member encoding gene, MACROD2 (macro domain containing 2) on chro‐
mosome 20p12 was also found on a separate chromosome in ASD GWAS [65, 188], so 
MACROD2 gene is a strong positional candidate risk factor for autistic‐like traits in the 
general population. The macrodomain of MacroD2 binds a cellular metabolite that emerg‐
es from histone deacetylation reactions linking both histone variant and histone modifica‐
tion events. There is also evidence that suggests that MACROD2 could act to regulate the 
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expression of the phospholipase D2 (PLD2) gene [65]. Phospholipase proteins could play 
an important role in risk for ASD. The protein derived from PLD2 has been shown to regu‐
late axonal growth [189] and metabotropic receptor signaling [190].
6.3.3. Mendelian ASD disorders in others chromatin remodelers and transcription factors
• ATP‐dependent chromatin remodeling complexes:
As we have detailed above, the importance of histones (particularly HAT and HDAC com‐
plexes) and chromatin structure in the regulation of eukaryotic gene transcription has become 
much more widely accepted over the past few years. Today it is known as a specific type of 
chromatin remodeling machine involved in transcription regulation and can use the energy 
of ATP hydrolysis to alter interactions between histones and DNA within the nucleosome. 
Changing chromatin states is an active process that requires appropriate external signal, as 
well as energy in the form of ATP. The engines that carry out the active process are called 
“ATP‐dependent chromatin remodeling complexes”; they utilize the energy from ATP hydro‐
lysis, and are key players in the reorganization and regulation of chromatin accessibility and 
nucleosome positioning on the eukaryotic DNA, regulating gene expression; and particularly 
modulates transient extracellular signals to influence neural lineage commitment [191]. These 
complexes contain an ATPase subunit that belongs to the SNF2 superfamily of proteins. Based 
on the identity of the sequence homology of their conserved ATPase domains, SNF2 proteins 
have been into three main groups, the SWI2/SNF2 group, imitation SWI (ISWI) group, and a 
third class that contain a SNF2‐like protein family ATPase and also show deacetylase activity. 
The diverse subunits together provide a multitude of functions, from early embryogenesis 
through cell differentiation to organogenesis (for review see [192–194]).
Several components of the ATP‐dependent SWI/SNF complex also known as the BAF com‐
plex, one of the best characterized ATP‐dependent chromatin remodeling complexes, are 
encoded by genes in which rare autism mutations have been observed, including ARID1A 
and ARID1B in Coffin‐Siris syndrome, ATRX in X‐linked alpha‐thalassemia/mental retarda‐
tion syndrome, and SMARCC1 (BAF 155) and SMARCC2 (BAF170) genes [195]. A neuron‐spe‐
cific protein ATPase subunit BAF53b defines a neuronal chromatin‐remodeling complex that 
is necessary for long‐term memory and synaptic plasticity in mice [196].
Forms of Coffin‐Siris syndrome (CSS) have been shown to be caused by mutations in each 
of five genes encoding subunits of the SWI/SNF complex. These include CSS1 caused by 
heterozygous mutation in the ARID1B gene (614556) on chromosome 6q25; CSS2 (614607), 
caused by mutation in the ARID1A gene (603024); CSS3 (614608), caused by mutation in the 
SMARCB1 gene (601607); CSS4 (614609), caused by mutation in the SMARCA4 gene (603254); 
and CSS5 (616938), caused by mutation in the SMARCE1 gene (603111) [197].
In addition, several exome sequencing studies in autism have identified rare mutations in 
genes encoding the ATP‐dependent chromatin helicases CHD8 (CHD8‐chromodomain heli‐
case binding protein 8) [198]. CHD8 is a chromatin remodeling ATPase of the SNF2‐like 
protein family and an important regulator of beta‐catenin and Wnt signaling pathways in neu‐
ronal development, and is typically involved in the regulation of gene expression (e.g., CHD8 
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insufficiency results in altered expression of 1715 genes, including both protein‐coding and 
noncoding RNAs) [199]. Another novel ATPase of SNF2‐like protein family termed ARIP4 
interacts with androgen receptors and modulates androgen‐dependent transcription [200].
• Transcription factors:
Transcription factor (TF) is a protein that binds to specific DNA sequences, just like that 
controlling the rate of transcription of DNA to mRNA. A defining feature of TF is that they 
include one or more DNA‐binding domains, which attach to specific sequences of DNA 
adjacent to the genes that they regulate [201]. At present there are numerous transcriptional 
changes associated with autism, so MECP2 gene is also a transcription factor.
 ○ ADNP: ASD caused by a mutation in ADNP, a transcription factor involved in the SWI/
SNF. ADNP is known to be mutated in at least 0.17% of ASD cases, making it one of the 
most frequent ASD genes known to date [202].
 ○ FOXG1: Overexpression of the transcription factor FOXG1 is responsible for the overpro‐
duction of GABAergic neurons. Altered expression of gene network modules and FOXG1 
are positively correlated with ASD symptom severity, and likely a shift toward GABAergic 
neuron fate caused by FOXG1 is a developmental precursor of ASD [104].
 ○ PITX1 (paired‐like homeodomain transcription factor 1) is a key regulator of hormones 
within the pituitary‐hypothalamic axis (as ACTH, cortisol, and betaendorphin) and may 
be implicated in the etiology of autism [187]. The ACTH‐cortisol system, which also plays 
an important role in stress‐related responses, is impaired in autistic individuals in whom 
lower cortisol levels and higher ACTH levels have been reported.
7. Acquired epigenetics disorders in ASD
Compared with the magnitude of genetic studies in ASD, nongenetic biological risk factors 
were studied to a lesser extent. Even though in the last decade, the number of publications 
that address epidemiological factors and autism has grown tremendously. Although there are 
numerous risk factors (prenatal, perinatal, and postnatal risk factors) that have been linked to 
autism [203–206], in some cases their involvement has been or is still considered controversial, 
and as a possible hypothesis, postulates that improvements in obstetric and neonatal manage‐
ment have resulted in an increased frequency of survivors with preexisting brain damage, 
which has subsequently led to autism [203]. For each infant, an environmental challenge dur‐
ing a critical window of development can have particularly serious consequences, causing the 
abnormal functioning of the CNS, perhaps autism.
Among the most significant environmental factors linked to epigenetic mechanisms in autism 
include the following (for review see [95, 110]).
7.1. Toxic exposures teratogens and medications
The particular vulnerability of the developing nervous system for low‐level exposure to 
chemicals is well established. Some degree of developmental neurotoxicity was found 
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for a large number of industrial chemicals and environmental pollutants. However, for 
only few of these (lead, arsenic, organic mercury, and polychlorinated biphenyls, PCBs), 
human moderate evidence has emerged for a potential role of environmental pollutants in 
neurodevelopmental adversity and may, thus, be involved in contributing to neurodevel‐
opmental disorders like autism, ADHD, ID, or cerebral palsy (for review see: [207–209]). 
However, the mechanisms by which environmental factors produce neurotoxicity dur‐
ing early development are not well stated. Heritable genetic vulnerabilities in ASD may 
amplify adverse effects triggered by environmental chemicals exposures if genetic and 
environmental factors converge to dysregulate the same signaling systems at critical times 
of development.
Among the several major signaling pathways linked to altered neuronal connectivity in the 
developing brain, as a convergent molecular mechanisms target of gene and environment 
chemicals interactions, they have been involved in dysfunctional signaling via cytokine 
dysregulation [210], Ca(2+)‐dependent mechanisms, extracellular signal‐regulated kinases 
(ERK)/phosphatidylinositol‐3‐kinases (PI3K), and neuroligin‐neurexin‐SHANK (for review 
see [211]). As well as, exposure to environmental chemicals (using PCBs, lead, and bisphenol 
A, BPA, as examples) may contribute to adverse neurodevelopmental outcomes of relevance 
to ASD via effects on DNA methylation in the developing brain (for review see [212]). In 
utero exposure to environmental pollutants increases autism‐like behavioral phenotypes in 
adult animals and induces epigenetic changes, so exposure to heavy metals resulted in mul‐
tiple behavioral abnormalities that persisted into adulthood. Valproic acid and manganese 
induced changes in perseverative/impulsive behavior and social dominance behavior, arsenic 
caused changes only in perseverative/impulsive behavior, and lead induced abnormalities in 
social interaction in comparison to the control animals. The Chd7 gene, essential for neural 
crest cell migration and patterning, was found to be hypomethylated in each experimental 
animal [213].
• Heavy metals like lead and mercury are widespread environmental toxins. Developmental 
exposure to these compounds is associated with lower IQ, endocrine disruptions, and 
behavioral disturbances. They also have immunotoxic properties. These features have 
made them possible, though controversial, candidates in ASD. There are conflicting reports 
regarding lead in autism. A few studies have documented higher serum lead levels [214] 
often associated with pica [215], although more recent studies show no difference between 
autism and control populations [216, 217]. Association between mercury levels and autism 
is also somewhat contradictory [218]. Ethyl mercury is a component in the vaccine preser‐
vative thimerosal, which has received attention in recent years. It has neurotoxic capacities, 
while in vitro studies suggest toxic potential for thimerosal (can alter calcium signaling and 
cytokine production), a large number of independent epidemiological studies show no 
link to autism [219, 220].
• Bisphenol A (BPA), an epoxy resin, is an endocrine‐disrupting chemical (xenoestrogen), 
employed to make certain polycarbonate plastic products as food containers and baby 
bottle, and it is the major estrogenic compound that leaches into nearby water and food 
supplies. BPA has been detected in 95% of human urine samples, which indicates that 
environmental exposure is widespread [221]. Exposure to BPA during development may 
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affect brain organization and behavior, perhaps as a consequence of its actions as a steroid 
hormone agonist/antagonist and/or as an epigenetic modifier that alters DNA methylation. 
Fetal and prenatal BPA exposure was suggested to perturb the serotonergic system in rat 
and mice models. Epigenetic mechanisms are suggested by a mouse study that demon‐
strated that BPA prenatal exposure had long lasting, transgenerational effects on social 
recognition [222]. BPA affects the mRNA levels (lower transcript levels) of several genes 
encoded for estrogen receptors, oxytocin, and vasopressin, recognized as important neuro‐
peptides modulators of various social behaviors. BPA is not metabolized well in children 
with ASD. The most recent FDA updates (Administration January 2010) points to “some 
concern about the potential effects of Bisphenol A on the brain, behavior, and prostate 
gland in fetuses, infants, and young children.” In France, BPA was banned in baby bottles 
in 2010, and in any food or beverage packaging since January 2015 [223].
• Other environmental pollutants and toxic products have also been controversial in its 
possible relationship with neurodevelopment and ASD. There was weak evidence of an 
association between nickel exposure during pregnancy and ASD [224]. Also, gestational 
exposure to inorganic arsenic (an important natural pollutant of water) affected the expres‐
sion of cysteine/glutamate transporters in the cortex and hippocampus and induced a neg‐
ative modulation of glutamate receptor N‐methyl‐D‐aspartate (NMDAR) subunits NR2A 
in the hippocampus. Behavioral tasks showed significant spatial memory impairment in 
males while the effect was marginal in females [225]. Developmental neurotoxicity and 
autism risk a positive association with pesticides (organochlorines, organophosphates, 
pyrethroids) [226, 227]; halogenated aromatic hydrocarbons [PCBs and polybrominated 
diphenyl ethers (PBDEs)] [210, 228].
• Exposure to drugs: Prenatal exposure to valproic acid, ethanol, thalidomide, and misopro‐
stol has been shown to be associated with an increased incidence of autism. These drugs 
are able to modulate the expression of many genes involved in processes such as prolif‐
eration, apoptosis, neuronal differentiation and migration, synaptogenesis, and synaptic 
activity [229]. Exposure to selective serotonin reuptake inhibitors (SSRI) in depressed preg‐
nant women might be involved in the etiology of autism, as well as the prenatal valproic 
acid (VPA) exposure, which is also thought to interfere with serotonin levels [230], by dis‐
ruption of early serotonergic neuronal development [231] or via the reduction of PTEN 
level [232].
Children exposed to valproate in utero were seven times more likely to develop autism than 
those not exposed to antiepileptic drugs. Qin et al. [233] have shown that VPA exposure 
sequentially activates Wnt signaling and mTOR signaling in rats. Suppression of the Wnt sig‐
naling pathway relieves autistic‐like behaviors partially by deactivating the mTor‐signaling 
pathway in VPA‐exposed rats.
As we have previously redesigned previous research has not been able to prove that admin‐
istrations of the measles‐mumps‐rubella vaccine were connected with the autism upsurge 
[6], but it has been suggested that acetaminophen systematically administered during vac‐
cination, may mediate oxidative stress and neurotoxicity in autism [234], and exposure 
during pregnancy enhances the probability of appearance of ADHD‐like behaviors [235]. 
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These are data from an ecological analysis, not considered optimal as evidence of causal‐
ity. Nonetheless, there is accumulating clinical and experimental evidence connecting acet‐
aminophen metabolism to biochemical routes known to be relevant for autism and related 
developmental disorders. Taking into account both ecological and mechanistic evidence, the 
role of acetaminophen in autism should be formally studied [236]. In rat liver, acetaminophen 
overdose has been implicated in Id2 (a pleiotropic protein whose function depends on its 
expression levels) down‐regulation vía histone‐H3 hypoacetylation [237].
7.2. Immune dysregulation or inflammation
The immune system and the nervous system interact widely. Therefore, it is not surprising 
that immune dysfunction is often observed in neurological disorders. There is accumulat‐
ing evidence for immune dysregulation playing a role in the pathogenesis of ASD. Early‐
life infections can skew fetal development, leading to aberrant neural and immune activity. 
Several infections [238, 239] including measles, cytomegalovirus, and rubella during pre‐ and 
perinatal periods have been associated with autism [240–244]. A large‐scale epidemiological 
study showed that infection‐related hospitalizations during pregnancy significantly increased 
the risk of ASD [245], and also worth noting is prenatal inflammation, particularly prenatal 
urinary tract infection [204]. A multidirectional interaction between immune system activa‐
tion in the mother during pregnancy and epigenetic regulation in the brain of the fetus may 
cooperate to produce an autistic phenotype. This interaction includes immune factor‐induced 
changes in epigenetic signatures in the brain, dysregulation of epigenetic modifications spe‐
cifically in genomic regions that encode immune functions, and aberrant epigenetic regula‐
tion of microglia (for review see [246]).
Numerous immune system abnormalities including T and B cell lineages of adaptive immune 
responses have been described in individuals with autism, for example:
FOXP3 (Forkhead box P3) is a marker of (+) regulatory T cells [T (Reg)] which are potent 
mediators of dominant self‐tolerance in the periphery. A subset of CD4+ T cells is primed 
in early life, to recognize common environmental antigens and inhibit later inappropriate 
immune responses. The expression of the FOXP3 locus is intimately linked to its chromatin 
structure [di‐ and trimethylation of lysine 4 of histone H3 (H3K4me2 and ‐3)]. Interestingly, T 
(Reg) fate determination is an epigenetic event of FOXP3 promoter demethylation induced by 
repeated Ca+2‐mediated signal transduction and prevented by the mTOR pathway [247,  248]. 
Abnormalities in the ratio of Th1/Th2/Th17 cells and T (Reg) cell‐related transcription fac‐
tor signaling in ASD is characterized by a systemic deficit of FOXP3+ (TReg) and increased 
RORγt+, T‐bet+, GATA‐3+, and production by CD4+ T cells [249].
Also immune aberrations, with increased levels of plasma cytokines, have been reported 
in ASD especially in those autistic children with a regressive form of the disease [250]; and 
mothers of children with ASD exhibit altered cytokine profiles and autoantibodies indica‐
tive of systemic immune activation [210]. There are many reports of cytokine imbalances in 
autism, including IL‐1B, IL‐6, IL‐4, IFN‐γ, and TGF‐B. Cytokines act mainly as mediators 
of immune activity, but they also have meaningful interactions with the nervous system. 
They take part in normal neural development and function, and improper activity can have a 
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variety of neurological implications. These imbalances could have a pathogenic role, or they 
may be markers of underlying genetic and environmental influences (for review see [210]). 
Histone modifications play critical roles in the regulation of the innate immune response; for 
example, histone lysine methyltransferase Ezh1 promotes TLR‐triggered inflammatory cyto‐
kine production by suppressing Toll‐interacting protein [251], and histone H3 phosphoryla‐
tion by IκB kinases‐α is critical for cytokine‐induced gene expression [252].
Even though infections and inflammation have profound effects on epigenetic modifications 
and trigger susceptibility to diseases as ASD, however, very little is known about the epigen‐
etic pathways involved in the modulation of inflammatory and anti‐inflammatory genes (for 
review see [246, 253]).
A novel unifying hypothesis of the etiopathogenesis of ASD for fitting the pieces of the puzzle 
together (collectively and simultaneously), suggest that ASD are disorders of the immune 
system that occur in a very early phase of embryonic development. In a background of genetic 
predisposition and environmental predisposition (like vitamin D deficiency), an infection 
(notably a viral infection) or food allergy could trigger a deranged immune response which, 
in turn, results in damage to specific areas of the CNS [254].
mTOR pathway: Postnatal pathogenic exposures and/or Immunological disturbances in 
autistic individuals have been reported and a role for food allergy has been suggested in 
ASD. Single gene mutations in mammalian target of rapamycin (mTOR) signaling path‐
way are associated with the development of ASD and enhanced mTOR signaling plays 
a central role in directing immune responses toward allergy as well [255, 256]. Multiple 
ASD syndromes are caused by mutations in genes that act to inhibit mTOR kinase, includ‐
ing Tsc1/Tsc2, NF1, and Pten [257]. In mouse models of ASD mTOR dysregulation causes 
spine‐pruning defects in Tsc‐deficient mouse [258]. Increased dendritic spine density with 
reduced developmental spine pruning in layer V pyramidal neurons are observed in post‐
mortem ASD temporal lobe, and these spine deficits correlate with hyperactivated mTOR 
and impaired autophagy [259]. Synaptic mTOR integrates signaling from various ASD 
synaptic and regulatory proteins, including SHANK3, FMRP, and the glutamate receptors 
mGluR1/5 [257, 260]. It has been proposed that mTOR pathway plays a central role in direct‐
ing immune responses toward allergy (e.g., cow's milk allergy, or valproic acid exposure) 
as well, and may be a pivotal link between the immune disturbances and behavioral deficits 
observed in ASD [233, 261, 262]. Inhibition of mTORC1 activity by rapamycin improved the 
behavioral and immunological deficits of cow's milk allergic mice [256]. And also, sulin‐
dac (nonsteroidal anti‐inflammatory drugs) by suppression of the Wnt signaling pathway 
relieves autistic‐like behaviors partially by deactivating the mTOR‐signaling pathway in 
valproic acid‐exposed rats [233].
7.3. Nutritional status
There is consensus that children with autism are nutritionally vulnerable because they have 
selective or picky eating patterns, food neophobia, limited food repertoire, and abnormal 
sensory processing (“neurosensorial aversion” can affect both the taste and the texture) that 
predisposes them to food avoidance and restricted food intake in many children with ASD 
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[263]. “Insistence on sameness” and compulsive repetitive behaviors reinforce rigid dietary 
preferences and lead to a limited food repertoire [264].
Although inadequate micronutrient but adequate macronutrient intakes are increasingly 
reported, there are inconsistent results about the extent and type of nutrient deficiencies (for 
review see [265]). Micronutrient as essential amino acids, minerals, and vitamins are indispens‐
able for human health, primarily due to their critical function as enzymatic cofactors for numer‐
ous reactions in the body, such as the production of neurotransmitters and fatty acid metabolism.
A growing body of literature suggests that certain modifiable risk factors such as maternal 
metabolic syndrome and nutritional risk factors as certain vitamins, like vitamin D, and folic 
acid either in utero or early life, may be associated with increased risk of autism [266]. Several 
studies with biomarkers of the nutritional and metabolic status of children with autism 
have demonstrated statistically significant differences in their nutritional and metabolic 
status, including biomarkers indicative of vitamin insufficiency, decreased glutathione and 
increased oxidative stress, reduced capacity for energy transport, sulfation and detoxifica‐
tion, and also impaired methylation [267–269]. Nutrition also influences programming of an 
offspring's epigenome, so nutritional factors, particularly folate, B vitamins (B2, B6, and B12), 
and choline, have been studied in ASD, and a likely pathway of this action is the one‐carbon 
metabolism cycle, including the folate metabolism, the methionine‐homocysteine remethyl‐
ation cycle (involving choline and betaine), and the transsulfuration pathway.
7.3.1. Amino acids
The essential amino acids tryptophan and serotonin are precursors of neurotransmitters. It 
has been seen that plasma‐free tryptophan and blood serotonin level are significantly higher 
in autistic children than in normal control subjects. These results suggest that autistic children 
have some defects in tryptophan‐serotonin metabolism in the brain [270]. And disorders of 
serotonin metabolism are associated with disturbances of platelet catecholamines, and also 
with elevated immunoglobulins and enhanced cellular immunity reactions [271].
Multivariate statistical analysis in children with autism from their unaffected siblings and age‐
matched controls, indicated urinary patterns of the free amino acids glutamate and taurine 
were significantly different between groups with the autistic children showing higher levels of 
urinary taurine and a lower level of urinary glutamate, indicating perturbation in sulfur and 
amino acid metabolism in these children [272]. The metabolomic analyses showed variations 
in essential amino acid metabolism pathways in children with ASD, related to lowered dietary 
protein intake or to abnormal catabolism, but their role in the etiology and therapeutic use are 
contradictory [273]. For body fluid levels of neuroactive amino acids, including glutamate, glu‐
tamine, taurine, gamma‐aminobutyric acid (GABA), glycine, tryptophan, D‐serine, and others, 
in ASD the results reported in the literature are generally inconclusive (for review see [274]).
7.3.2. Minerals
• Iron is critical for early neurodevelopmental processes. Low serum iron occurs more fre‐
quently in children with autism compared with children with typical development. The 
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prevalence of iron deficiency and anemia in subjects with autism is reported between 24 
and 32% and 8 and 16%, respectively. Because iron deficiency, with or without anemia, 
results in impaired cognition and developmental defects, iron deficiency in children with 
autism could further compromise their communication and behavioral impairments [265]. 
Thus, ferritin levels should be measured in subjects with autism as a part of routine inves‐
tigation [275]. Studies consistently show link between maternal supplemental iron and 
ASD. Maternal intake of supplemental iron (from 3 months before pregnancy through the 
end of pregnancy and during breastfeeding) was associated with reduced ASD, especially 
during breastfeeding. Low iron intake significantly interacted with advanced maternal age 
and metabolic conditions [276].
• Other minerals: Yasuda et al. [277] examined scalp hair concentrations of 26 trace elements 
for 1967 children with autistic disorders and found deficient in zinc (29.7%), magnesium 
(17.6%), and calcium (5.8%); and 2.0% or less in other essential metals. The incidence rate 
of mineral deficiency was highly observed in infants aged 0–3 years old. By contrast, indi‐
viduals were found suffering from high burden of aluminum (17.2%), cadmium (8.5%), 
and lead (4.8%), and 2.8% or less from mercury and arsenic burden. Findings by other 
authors also include deficient in: calcium [269, 278], magnesium [269, 279], iodine [269], 
chromium [269], and selenium [279]. These findings suggest that infantile zinc and mag‐
nesium deficiency and/or toxic metal burdens may epigenetically play principal roles as 
environmental factors in autistic disorders. Also compared with controls and/or reference 
ranges of healthy children, children with autism have lower concentrations of lithium 
[269]. Low concentrations of lithium are particularly interesting because its deficiency has 
been linked to a wide range of psychiatric disorders including autism. The low concentra‐
tions of lithium can be translated into decreased activity of enzymes involved in growth 
factor signaling pathways and regulation of neurotransmitter, and suggest that low‐level 
lithium supplementation may be beneficial for mood stabilization in this group [280].
7.3.3. Vitamins
Children with autism had many statistically significant differences in their nutritional and 
others vitamin insufficiency, such as low levels of vitamin D, vitamin B6, biotin, vitamin A, 
and vitamin C, and also trend toward lower levels of vitamin B5 and vitamin E, and total 
carotenoids, although could not objectify constant data for different populations [269, 281].
• Dietary vitamin D could regulate epigenetic machinery. Epidemiologic evidence support‐
ing the role of vitamin D deficiency either during pregnancy [282, 283] or early childhood 
may be an environmental trigger for ASD in individuals who are genetically predisposed 
(for review see [254, 284, 285]). Vitamin D and its receptor (VDR) also known as calcitriol 
receptor NR1I1 (nuclear receptor subfamily 1, group I, member 1) belongs to the family of 
trans‐acting transcriptional regulatory factors, and are involved principally through two 
main areas: (1) in the brain homeostasis and mineral metabolism the receptor regulates 
a variety of other metabolic pathways and several genes controlling anti‐inflammatory 
actions, immune response, and neurodevelopment (cellular proliferation, differentiation, 
and apoptosis); mainly vitamin D might play a role in the regulation of the production of 
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autoantibodies not only through modulation of T‐helper cell function, but also through 
induction of CD4(+)CD25(high) regulatory T cells. Vitamin D might also protect the mito‐
chondria, and upregulate glutathione, which scavenges oxidative by‐products and che‐
lates (captures and excretes) heavy metals. (2) In gene regulation the calcitriol receptor 
play ball with some chromatin modification enzymes (i.e., histone acetyltransferases and 
histone deacetylases), taking a role in complex epigenetic events [285, 286].
Recent studies in ASD children have shown that fifty‐seven 40–57% of the patients had vitamin 
D deficiency (serum 25‐OHD levels10–30 ng/mL), and 30–48% had vitamin D insufficiency 
(serum 25‐OHD levels <10 ng/m); also in patients with severe autism the mean 25‐OHD levels 
were significantly lower than those in patients with mild/moderate autism. Increased levels 
of serum anti‐MAG autoantibodies were found in 70% of autistic patients; and this deficiency 
may contribute to the induction of the production of serum anti‐MAG autoantibodies in these 
children [287]. Additionally, vitamin D supplementation may have beneficial effects in ASD 
subject [288].
• Vitamin B complex
 ○ Folic acid and folate (anionic form) also known as vitamin B9, is a water‐soluble vitamin, 
listed in vitamin B complex, necessary for the formation of structural proteins and hemo‐
globin and are essential for basic cellular processes including DNA replication as well as 
DNA, RNA, and protein methylation. Folic acid is essential for the proper development 
of the central nervous system, and their deficiency during pregnancy has been associated 
with a wide range of disorders. Randomized controlled trials have found that periconcep‐
tional folic acid supplementation reduces the risk of neural tube birth defects up to 70%. 
So, in several countries, public health policies recommend periconceptional supplementa‐
tion with folic acid (400 μg/d) to decrease the risk of neural tube defects [289]. But also find‐
ings from a large multicenter case‐control study, CHildhood Autism Risks from Genetics 
and Environment (CHARGE), suggest that periconceptional folic acid may reduce ASD 
risk in those with inefficient folate metabolism [290].
The vitamin folate regulates the metabolic pathway catalyzed by the methylenetetrahy‐
drofolate reductase (MTHFR), encoded by the MTHFR gene (locus 1p36.3), it is the rate‐
limiting enzyme in the methyl cycle and a key source of the “one‐carbon group,” it acts 
as methyl donor (for homocysteine remethylation to methionine), which critically influ‐
ences in epigenetic mechanisms to methylate DNA (for review see [291]). But the genomic 
regions in the offspring that may be sensitive to folate exposure during in utero develop‐
ment have not been characterized. Genome‐wide DNA methylation profiling identifies a 
folate‐sensitive region of differential methylation upstream of ZFP57‐imprinting regula‐
tor in humans [292]. The underlying mechanisms of action also includeregulation of two 
microRNAs—let‐7 and miR‐34—by methylation [293].
The time period at which periconceptional folic acid was added to the diet of women of 
childbearing age coincides with the seeming onset of a steady increase in the prevalence 
of autism. Some studies have reported that periconceptional folic acid supplementation, 
depending on timing and dose, could be associated with a higher incidence of autism. But 
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nevertheless, a recent meta‐analysis shows that the few and contradictory studies present 
inconsistent conclusions, and epidemiological associations are not reproduced in most of 
the other types of studies [294]. On the other hand, a well‐controlled epidemiological study 
including a sample of 85,176 children disconfirms this claim and reports a lower incidence 
of ASD in children whose mothers received prenatal folic acid supplementation around 
the time of conception (0.10%) compared with those unexposed to folic acid (0.21%) [295]. 
However, these findings have not been verified in other studies [296]. This could be attrib‐
uted to periconceptional folic acid, which may reduce ASD risk in those with inefficient 
folate metabolism (for mothers and children with MTHFR variant genotypes, like MTHFR 
C677T polymorphism) [290, 297]. Besides, folate receptor autoantibodies (FRAs) that 
interfere with folate transport across the blood‐brain barrier may be important in ASD 
(a high prevalence to 75.3%) and that FRA‐positive children with ASD may benefit from 
leucovorin (folinic acid) treatment [298]. Also, some studies have reported lower folate 
levels in patients with ASD [299, 300] and high levels of homocysteine [299, 301]. Folic acid 
supplementation may have a certain role in the treatment of children with autism, and this 
treatment also improved the concentrations of folic acid, homocysteine, and normalized 
glutathione redox metabolism [302]; but the effects of folate‐enhancing interventions on 
the clinical symptoms have yet to be confirmed [294].
• B‐Group vitamins B2, B6 and B12:
Studies in autistic children report decreased concentrations likely below the reference 
range of vitamin B‐12 and folate by dietary deficits [300]. Vitamin B6 and B12 (or cobala‐
min) acts as coenzymes in the metabolism, with a close metabolic interrelation in the meth‐
ylation of homocysteine to obtain methionine (Met). The name “one‐carbon metabolism” 
involving folic acid, vitamins B2, B6, and B12, and folate metabolism does not only gener‐
ate methyl groups, thus determining epigenetic processes, modifications of the genome 
and carcinogenesis, it also provides the compounds involved in the DNA synthesis and 
repair processes, especially the synthesis of purines and pyrimidines [303]. Nutritional 
supplementation with vitamin methyl‐B12, folinic acid, and trimethylglycine might be 
beneficial on glutathione redox status in children with autism [304].
Elevated and unusually broad vitamin B‐6 (pyridoxine) concentrations have been reported 
in children with autism which may be due to low activity of pyridoxal kinase that converts 
pyridoxal and pyridoxine into the active form pyridoxal 5‐phosphate (P5P), which is the 
active cofactor for several enzymatic reactions, including the formation of many key neu‐
rotransmitters [305]. This explains the benefits of high‐dose vitamin B‐6 supplementation 
in individuals with autism with low P5P [269, 306].
 ○ Biotin or vitamin B7 (and also H or B8) is a water‐soluble vitamin involved in the metabo‐
lism of carbohydrates, fats, amino acids, and purine. Decreased concentrations below the 
reference range of biotin have been reported in nutritional status of children with autism 
[269]. Also, it is evident for treatable inborn errors of metabolism patients with ASD. So 
detailed metabolic revealed biomarkers (urine 3‐hydroxyisovaleric acid and serum beta 
hydroxybutyrate) in 7% of patients for whom biotin supplementation resulted in mild to 
significant clinical improvement in autistic features [307].
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7.3.4. Vitamin‐like substances: choline
Other nutrients whose effects are similar to those of vitamins including choline and is among 
the most prominent associated with ASD. Choline is an essential nutrient soluble in water 
usually grouped with B vitamins. Choline is an endogenous compound that is synthesized 
by all cells of mammals, as an intermediary in the major route of transformation of the hill in 
phosphatidylcholine, an essential phospholipid of the neuronal membrane in the CNS and is 
essential for proper brain maturation, including astroglia. Choline is a major source of methyl 
groups needed for methylation of DNA and histones [308]. There is growing evidence that 
this nutrient also modulates epigenetic regulation of gene expression in both neuronal and 
endothelial progenitor cells, thereby modifying brain development [309].
Choline is the precursor for betaine and methyl groups derived from betaine, which are used 
for S‐adenosylmethionine (SAM)‐dependent methylation reactions including the synthesis of 
membrane phosphatidylcholine. In this way, choline indirectly serves as a precursor for the 
synthesis of membrane phospholipids that are essential for normal membrane fluidity, signal 
transduction, membrane transport, and integrity for synaptic efficiency. Choline is needed 
by fetal progenitor cells (proliferate, migrate, differentiate, and undergo apoptosis at specific 
times during fetal development) for membrane synthesis and for methylation (redox‐depen‐
dent methylation regulates neuronal mRNA). Choline is also a precursor for the synthesis of 
acetylcholine (ACh), an important neurotransmitter in both the central and autonomic ner‐
vous systems [310, 311].
Inadequate choline and betaine can negatively affect folate‐dependent “one‐carbon metab‐
olism” and in turn downstream methylation and antioxidant capacity (Figure 1.) The 
metabolism of folate, vitamin B12, vitamin B6, choline, and methionine are interrelated and 
disturbances in one of these metabolic pathways are associated with compensatory changes 
in the others. So, when humans and animals are fed a diet deficient in choline, it increases the 
need for dietary folate [312, 313]. Alternatively, if they are fed a diet deficient in folate, dietary 
choline requirements increase as choline becomes the primary methyl group donor [314–316].
Choline is found primarily in foods that contain fat and cholesterol, and intake of such foods 
has decreased in recent years. Estrogen induces the gene for enzyme that catalyzes the bio‐
synthesis of the choline‐containing phospholipid phosphatidylcholine. Nevertheless, many 
women have a SNP that blocks the induction of endogenous biosynthesis, which makes lon‐
ger requirement of choline in the diet. When these women consume diets low in choline, it is 
likely to be in insufficient supply of this nutrient for the fetus, and may disrupt the progenitor 
cell proliferation, migration, differentiation, and apoptosis [309].
Low plasma SAM levels and DNA hypomethylation have been shown to be present in chil‐
dren with autism [107]. Choline deficiency has been also shown in animal models to contribute 
to global and gene‐specific DNA hypomethylation and epigenetic abnormalities [317]. There 
are inconsistent findings on the amounts of free/total choline in autistic individuals. Free cho‐
line levels were similar in the autistic and control groups, but total choline was 17% higher 
in the autistic group (p < 0.0001) [269]. Hamlin et al.'s [318] study of 288 children with autism 
found that 69–93% had less than adequate choline intake, and 18–30% had betaine intake of 
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<3.5 mg/Kg. Lower choline and betaine intakes were also correlated with lower plasma choline 
and betaine concentrations among children with ASD. This suggests that the choline‐betaine‐
homocysteine pathway for Met synthesis may be compromised in children with ASDs.
In a rat model of diet‐induced fetal‐neonatal iron deficiency, the choline supplementation 
reduced the effects of iron deficiency, including those on gene networks associated with 
autism [319]. And also prenatal choline supplementation mitigates the adverse effects of pre‐
natal alcohol exposure on development in rats [320]. A pilot study suggests that an additional 
evaluation of choline supplementation as an intervention for memory functioning in children 
with fetal alcohol spectrum disorders is warranted [321]. We have observed improvement 
after administration of citicoline in a patient with autism and X‐chromosome‐linked ichthyo‐
sis caused by deletion Xp22.3‐pte; thanks to the role this nootropic plays in the biosynthesis 
of structural phospholipids involved in the formation and repair of the neuronal membrane, 
and a possible contribution of the gene PNPLA4, which codes for calcium‐independent phos‐
pholipase A2 beta, involved in lipoprotein metabolism [127]. Future research should consider 
whether these metabolic imbalances could be corrected with dietary counseling or supple‐
ment interventions.
7.3.5. Fatty acids (FAs)
The inability of the human body to synthesize acid, known as essential fatty acids (EFAs), 
implies that they must be obtained through diet or supplementation. The EFAs are all 
omega‐3 and ‐6 methylene‐interrupted fatty acids. Polyunsaturated fatty acids (PUFA) are a 
family of lipids including some subgroups identified by the position of the last double bond 
in their structure. PUFA omega‐3 fatty acids (n‐3 or ω‐3) include alpha linolenic acid (ALA), 
eicosapentaenoic acid [EPA, 20:5 (3)], and docosahexaenoic acid [DHA, 22:2 (3)], while PUFA 
ω‐6 include linoleic acid [LA, 18:2 (6)] and arachidonic acid [AA, 20:4 (6)].
Figure 1. “One‐carbon metabolism” implication in epigenetics.
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The CNS is rich in PUFAs, and in particular AA and DHA are essentials for brain development 
and play a key role in the maturation and signaling of the brain network. Clinical and ani‐
mal studies illustrate the importance of long‐chain polyunsaturated fatty acids (LCPUFAs) in 
neural development and neurodegeneration and FAs metabolic pathways may affect proper 
functioning of the CNS [322]. However, whether or not the levels of these PUFAs are altered 
in individuals with autism remains debatable.
In female mice maternal ω‐3 PUFA deficiency during pregnancy and lactation imprints 
long‐term changes of brain development neurogenesis and apoptosis in adult offspring, 
associated with DNA methylation of brain‐derived neurotrophic factor transcripts [323]. 
Children with ASD had lower dietary consumption of foodstuff containing DHA, as well 
as lower serum levels of DHA than controls [324]. In an analysis of the FAs composition of 
red blood cell (RBC) membrane phospholipids showed that the percentage of total PUFA 
was lower in autistic patients than in controls; and levels of AA and DHA were particularly 
decreased (p < 0.001) [325]. Reported abnormalities associated with the synthesis of lipid 
bilayer in ASD as a result of FAs insufficient dietary supplementation or genetic defects 
can contribute to the symptomatology of autism and individual variety (for review see 
[326]). A growing body of evidence suggests that individuals who have ASD may have 
low levels of these PUFAs, particularly DHA and the AA:DHA ratio. Studies also reported 
significantly higher plasma in the ratios: EPA:AA; linoleic acid:AA; a‐linolenic acid:DHA; 
and ω‐3 to ω‐6 FA ratios [327–329]. In ASD genetic abnormalities have been reported in the 
enzymes involved in phospholipid metabolism; e.g., functional abnormalities of the solute 
carrier 27A (SLC27A) gene family encoding fatty acid transport proteins (FATPs) [330]. 
But there appears to be no evidence of altered phospholipid‐related signal transduction in 
autism [331].
On the other hand, deficits associated with the release of AA from the membrane phospholip‐
ids and its subsequent metabolism to bioactive prostaglandins via phospholipase A (2)‐cyclo‐
oxygenase biosynthetic pathway have been shown. So, plasma levels of the proinflammatory 
AA metabolite prostaglandin E2 (PGE2) [325, 331, 332] and leukotrienes (two important lipid 
mediators) as well as isoprostanes (as marker of oxidative stress) recorded significantly ele‐
vated levels in autistics participants compared to controls [333]. The COX/PGE2 pathway and 
plasma transferrin (an iron mediator related to eicosanoid signaling) play an important role in 
synaptic plasticity and may be included in pathophysiology ASD [333]. In addition, Wong et 
al. [334] found that PGE2 activated the canonical Wnt signaling pathway and Wnt‐dependent 
migration and proliferation in neuroectodermal stem cells. In Wnt‐induced cells the level of 
β‐catenin protein was increased and the expression levels of Wnt‐target genes (Ctnnb1, Ptgs2, 
Ccnd1, Mmp9) was significantly upregulated in response to PGE2 treatment. This confirms 
that PGE2 activated the canonical Wnt signaling pathway. Furthermore, the upregulated 
genes have been previously associated with ASD.
There is strong mechanistic evidence to suggest that vitamin D and n‐3 LCPUFAs, specifically 
DHA, have the potential to significantly improve the symptoms of ASD [335]. But the efficacy 
of Omega‐3 FA supplementation in terms of ASD‐symptom management is controversial, 
so many authors show that DHA supplementation does not improve the core symptoms of 
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autism [336, 337]. A Cochrane review did not find any evidence of effects of omega‐3 FA in 
ASD [338]; by contrast, a recent study by Mazahery et al. [339] have shown that either vitamin 
D, DHA, or both are effective; the trial would reveal a noninvasive approach to managing 
ASD symptoms.
7.4. Gastrointestinal dysbiosis
Gut bacteria are an important component of the microbiota ecosystem in the human gut. 
The intestinal flora is composed of more than 1014 bacteria spread over more than 400 spe‐
cies, of which between 30 and 40 are dominant. The profile of an individual's microbiota is 
continually influenced by a variety of factors, including but not limited to genetics, age, sex, 
diet, and lifestyle. Although the microbial profile of each person is different, the relative 
abundance and distribution of bacterial species is similar among healthy individuals. All 
these bacteria, in continuous competition, produce a huge variety of enzymatic reactions 
that necessarily interact with the metabolism and physiology of the host (nutritional func‐
tions, immunological, toxicological, etc.), in situations of health or disease in the intestine. 
Activity microbial biochemistry acts collectively like an organ, intervening in the improve‐
ment of nutrient bioavailability and degradation of compounds from the nondigestible diet, 
the supply of new nutrients, and the elimination of harmful and antinutritional compounds. 
However, they can also be potentially harmful due to the change of their composition when 
the gut ecosystem undergoes abnormal changes in the light of the use of antibiotics, illness, 
stress, aging, bad dietary habits, and lifestyle. Perturbations in gut microbiome composi‐
tion have an emerging role in health and disease including brain function (development of 
emotional behavior, stress‐ and pain‐modulation systems, and brain neurotransmitter sys‐
tems); but also may be environmental contributors in neurodevelopmental disorders includ‐
ing ASD. The ability of the intestinal microbiota to communicate bidirectionally with the 
brain, known as the “gut‐brain axis,” in modulating human health by multiple mechanisms, 
including endocrine and neurocrine pathways, is at the forefront of current research [340, 
341]. There is still debate as to whether or not these changes are core to the pathophysiology 
or merely epiphenomenal [342].
An inconsiderable number of patients with ASD have a history (fetal, neonatal, and infant) 
of previous antibiotic exposure or hospitalization and GI symptoms; it is important to think 
about the importance of perturbations in gut microbiome during the first postnatal years of 
life in modulation of brain development, cognitive functions, and behavior [343]. In the first 
year of life, decreasing maternal immune protection and child immune system immaturity 
create an immune vulnerability to disease infection, especially if it is treated with antibiotics, 
and could facilitate gastrointestinal disorders and dysbiosis. This condition causes a vicious 
circle between the deterioration of the immune system and increase dysbiosis leading to leaky 
gut and neurochemical compounds and/or neurotoxic xenobiotics production and absorp‐
tion. This alteration affects communication “gut‐brain axis” that connects the intestine to the 
CNS through the immune system [344].
The complex carbohydrates (oligo‐ and polysaccharides) provided by diet are the group of 
fermentable substrates most abundant. Members gut flora has developed a complex system 
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of glycohydrolases that allow them to use, thus favoring survival, while generating meta‐
bolic energy for enterocytes. Main products of fermentation (enteric bacterial metabolites) 
are enteric short‐chain fatty acids (SCFA) mainly propionic (PPA), butyric acid (BA), and 
acetic acid, which constitute between 83 and 95% of the total SCFAs. SCFAs represent a 
group of compounds derived from the host microbiome that are plausibly linked to ASDs. 
Intraventricular administration of PPA and SCFAs in rats induces abnormal motor move‐
ments, repetitive interests, cognitive deficits, perseveration, and impaired social interactions. 
The brain tissue of PPA‐treated rats shows a number of ASD‐linked neurochemical changes, 
including innate neuroinflammation, increased oxidative stress, glutathione depletion, and 
altered phospholipid/acylcarnitine profiles. These directly or indirectly contribute to acquire 
mitochondrial dysfunction via impairment in carnitine‐dependent pathways; common anti‐
biotics may impair carnitine‐dependent processes by altering gut flora favoring PPA‐produc‐
ing bacteria and by directly inhibiting carnitine transport across the gut [345]. GI microbiota 
and their fermentation products are of potential use as biomarkers for early identification 
of the etiology and/or symptoms of ASD [346]. Therefore, a significant number of autistic 
children with chronic digestive disease (most with ileo‐colonic lymphoid nodular hyper‐
plasia and inflammation of the colorectum, small bowel and/or stomach) had low serum 
levels of myeloperoxidase (MPO). However, there was no significant relationship between 
these levels and severity of GI disease, including the presence of antineutrophil cytoplasmic 
antibodies (ANCA) [347]. Also, slow intestinal transit contributes to elevate urinary p‐cresol 
level in autistic children [348]. But metabolomics studies in ASD are far to be definitive and 
univocal [349].
By establishing the hypothesis the role that enteric SCFA, particularly PPA, produced from 
ASD‐associated gastrointestinal bacteria, may be a potential environmental trigger in some 
forms of ASD. Propionic acid has bioactive effects on (1) neurotransmitter systems, (2) intra‐
cellular acidification and calcium release, (3) fatty acid metabolism, (4) gap junction gating, 
(5) immune function, and (6) alteration of gene expression [350]. SCFA acts as gut‐related 
environmental signals and are capable of altering host gene expression (including CREB‐
dependent catecholaminergic neurotransmission), partly due to their histone deacetylase 
inhibitor activity and induced broad alterations in gene expression including neurotrans‐
mitter systems (monoaminergic pathways) neuronal cell adhesion molecules, inflammation, 
oxidative stress, lipid metabolism, and mitochondrial function, all of which have been impli‐
cated in ASD [351].
This modulation of the intestinal microbiota is currently a growing area of investigation and 
it just might be the key to treatment [352]. Studies have also suggested that the intestinal 
microbiota may be modulated with the use of prebiotics, probiotics, symbiotics, postbiotics, 
antibiotics, and fecal microbiota transplants and activated charcoal, as an opportunity for 
therapy in microbiota‐associated diseases as ASD [353]. The literature contains information 
about autism being improved after treatment with common antibiotics (amoxicillin) [354]. 
Also, ceftriaxone, a beta‐lactam antibiotic, increases the expression of the glutamate trans‐
porter 1 which decreases extracellular glutamate levels. It is hypothesized that modulating 
astrocyte glutamate transporter expression by ceftriaxone or cefixime might improve some 
symptoms of ASD [355].




Stressor exposure during early life has the potential to increase an individual's susceptibility 
to a number of neuropsychiatric conditions as anxiety disorders. In the gene‐environment 
interactions underlying ASD, also are implicate early prenatal stress as being especially det‐
rimental to boys with a vulnerable genotype. So, stressful events during pregnancy signifi‐
cantly predicted autistic traits in the offspring in males only [356].
The mechanisms underlying in the nature of this vulnerability have not yet been established. 
Potentially, etiologic mechanisms of the early postnatal stress including genes involved in the 
regulation of hypothalamic‐pituitary‐adrenal axis could be involved. Therefore, in autistic 
individuals a lower cortisol and higher ACTH levels is described [357, 358]. In experimental 
animals early life stress increases stress vulnerability through BDNF (brain‐derived neuro‐
trophic factor) gene epigenetic changes with decreased levels of acetylated histone H3 and H4 
[359]. Recent human epidemiological and animal studies indicate that stressful experiences 
in utero or during early life may increase the risk of neurological and psychiatric disorders, 
arguably via altered epigenetic regulation and transgenerational epigenetic inheritance (for 
review see [360]).
7.6. Others prenatal and perinatal environmental factors
7.6.1. Prenatal risk factors
Among the risk factors described for children with ASD those related to the gestational period 
should be noted. The pregnancy‐related risk factors that have been associated with ASD 
account for few cases, but show the importance of susceptibility of developing brain for cer‐
tain noxas. As previously mentioned the importance of teratogens toxic, nutritional factors, 
and immune system, among other factors, has been implicated as prenatal environmental 
risk. Among these risk factors it should be noted among other things:
• Maternal chronic disease, like maternal diabetes, prepregnancy obesity, and pre‐eclamp‐
sia, is modifiable environmental factor in ASD pathophysiology. Similarly, studies on 
maternal autoimmune disorders during pregnancy have reported different associated 
disorders (psoriasis with ASD; thyroid antibodies with ADHD) [361]. Group B strepto‐
coccus (GBS) is the most frequent commensal bacterium colonizing or infecting pregnant 
women. SGB is present in the lower genital tract of 15–30% of healthy pregnant women. 
In experimental animals, first time gestational exposure to GBS, autistic‐like behavior has 
been reported predominantly affecting male. So, GBS‐induced maternal immune activa‐
tion plays a role in offspring perinatal brain damage (white matter injury) and subsequent 
neurodisabilities such as autism [362, 363].
• Maternal smoking during pregnancy: Growing evidence links prenatal exposure to 
maternal smoking with disruption of DNA methylation (DNAm) profile in the blood 
of newborns. An EWAS was conducted using linear regression of methylation values 
against in utero smoke exposure; this study confirms differential methylation in MYO1G, 
CNTNAP2, and FRMD4A [364]. The association between maternal smoking during preg‐
nancy and ASD risk in offspring has been investigated in several studies, but the evidence 
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is not  conclusive. A recent meta‐analysis (including 15 observational studies with 17,890 
ASD cases and 1,810,258 participants) indicates that maternal smoking during pregnancy 
is not associated with ASD risk in offspring [365].
• Advancing paternal and grandpaternal age and risk of autism: the father's age is not a 
factor gene (with genetic implications), which has been associated with ASD, especially in 
sporadic cases. In men, with age increase de novo mutations in their germ cells and there is 
a greater chance that the children carry a harmful mutation that could increase susceptibil‐
ity to these disorders [366, 367]. Further, it identifies an association between advanced age 
(50 or older) males’ grandparents when they had their children and diagnosis of autism in 
the grandsons [368].
7.6.2. Perinatal and neonatal risk factors
Numerous risk factors perinatal and neonatal have been studied in relation to autism, and 
although there is insufficient evidence to implicate any factor perinatal or neonatal in the 
etiology of autism, however, there is some evidence to suggest that exposure to a broad class 
of conditions reflecting general commitments for perinatal and neonatal health may increase 
the risk [369], with special mention to prematurity [370, 205]. The prevalence (in the range 
3.65–12.9%) of ASD among preterm births is 10–12 times more than in the general popula‐
tion [371, 372]. The ASD diagnosis was associated with shorter gestation times and longer 
hospital stays [373]. Preterm children with very low birth weight (VLBW; 1000–1500 g) or 
extremely low birth weight (ELBW; under 1000 g) are at increased risk for ASD [374–376]. A 
number of hypotheses have been put forward to explain these high rates of ASD: prenatal and 
neonatal complications like sensory impairment associated with prematurity, white matter 
abnormalities, and cerebellar impairment which occurred more commonly among preterm 
infants [372, 377, 378]; as well as altered androgen exposure observed in premature infants 
[379]. Also, gene‐environment interactions and prematurity may combine to increase the risk 
for poor neurodevelopmental outcomes [380]. Thus, fetal membranes from spontaneous pre‐
term birth demonstrate differences in OXTR methylation and regulation and expression, but 
not in SHANK3, BCL2, and RORA, which suggest that epigenetic alteration of OXTR in fetal 
membrane may likely be indicating an in utero programming of this gene and serve as a sur‐
rogate in a subset of spontaneous preterm birth [381].
Other risk factors involved in the neonatal period include: higher incidence of hyperbilirubine‐
mia [205, 382], birth defect, a birth weight small for gestational age, acute fetal distress, difficult 
labor and respiratory infection [204], delayed birth cry and birth asphyxia [205], or low Apgar 
scores [203]. Factors associated with autism risk in a meta‐analysis of 40 studies in 2007 [369] 
were abnormal presentation, umbilical‐cord complications, fetal distress, birth injury or trauma, 
multiple birth, maternal hemorrhage, summer birth, low birth weight, small for gestational age, 
congenital malformation, low 5‐minute Apgar score, feeding difficulties, meconium aspiration, 
neonatal anemia, ABO or Rh incompatibility, and hyperbilirubinemia. But the authors conclude 
that there is insufficient evidence to implicate any one perinatal or neonatal factor in autism 
etiology, although there is some evidence to suggest that exposure to a broad class of conditions 
reflecting general compromises to perinatal and neonatal health may increase the risk.




Although the knowledge about risk factors for ASD increases day by day, the biological basis 
of ASD remains largely elusive. Up to now, a large percentage of publications have implicated 
physiological and metabolic abnormalities (examining peripheral biomarkers such as blood 
and urine) in ASD and other psychiatric disorders. In particular, “four major areas” have been 
seen to be involved: immune dysregulation or inflammation, oxidative stress, mitochondrial 
dysfunction, and environmental toxicant exposures. More recent studies have also reported 
these physiological abnormalities in brain tissue derived from individuals diagnosed with 
ASD, suggesting that ASD has a clear biological basis with features more related to known 
“medical disorders” than “psychiatric disorders.”
Genes implicated in ASD alter ratios of excitatory to inhibitory signaling in the CNS (with 
increased ratio of excitation/inhibition in key neocortical systems) affecting molecular path‐
ways and mechanisms related to synaptic dysfunction, in a process known as “developmental 
synaptopathy.” The interplay between mutations in different genes can produce “idiopathic” 
autism, but the exposure to environmental modifiers as well as the epigenetic factors may add 
up to a varying expression of autistic features, allowing to include autism among the “synaptic 
and chromatin‐remodeling disorders.” In the last years, the role of nutritional and metabolic 
status in ASD has also gained importance, particularly the “one‐carbon metabolism cycle,” 
including the folate metabolism, the methionine‐homocysteine remethylation cycle (involv‐
ing choline and betaine), and fatty acid metabolism, as well as alterations in gut microbiome 
composition of children with autism. Furthermore, research in these physiological areas may 
lead to breakthroughs, in general, as well as subset‐specific processes, that could contribute to 
elucidate the development of ASD. Epigenetic studies besides being useful to discover causal 
factors, they may also help to unravel the physiological mechanisms predisposing or result‐
ing from the onset of ASD. Therefore, it is also important to follow the epigenetic approach to 
investigate the possible impairment of metabolic systems in ASD as well as in the search for 





ASD autism spectrum disorder
BA butyric acid
BDNF brain=derived neurotrophic factor
BPA bisphenol A
BWS Beckwithâ€“Wiedemann syndrome
CDD childhood disintegrative disorder
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CDC Centers for Disease Control and Prevention
CSS Coffin=Siris syndrome
CMA chromosomal microarray analysis
CNS central nervous system.
CNV copy number variants
DD developmental delay
DSM Diagnostic and Statistical Manual of Mental Disorders
EFAs essential fatty acids
EWAS epigenome=wide association study
FAs fatty acids
FXS Fragile X syndrome




hiPSCs human induced pluripotent stem cells
HMTs histone methyltransferases
ICR imprinting control region
ICSI intra=cytoplasmic spermatozoid injection
ID intellectual disability
IVF in vitro fertilization
KDMs histone lysine demethylases
KMTs histone lysine methyltransferases
LCPUFAs long=chain polyunsaturated fatty acids
LCRs low=copy repeats
MBDs methyl=CpG=binding domain proteins
MCA multiple congenital anomalies
mPFC medial prefrontal cortex






PBDEs polybrominated diphenyl ethers
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